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ABSTRACT

Morrow, Marie Elizabeth. Ph.D., Purdue University, May 2015. Structural and
Biophysical Analysis of the Proteasomal Deubiquitinase, UCH37. Major
Professor: Chittaranjan Das.

Ubiquitin carboxyl-terminal hydrolase 37, or UCH37, is a deubiquitinating
enzyme associated with the 26S proteasome, the primary protein degradation
machinery in eukaryotic cells. UCH37 is responsible for the disassembly of
polymeric ubiquitin chains, or polyubiquitin, which have been ligated onto
proteins in order to target them for degradation. The 26S utilizes two associated
deubiquitinating enzymes, UCH37 and USP14, and one intrinsic, Rpn11, to
remove polyubiquitin chains from substrate proteins as they are unfolded and
translocated into the proteolytic core of the proteasome, where proteins are
cleaved into small peptides and then released for recycling by the cell. UCH37
associates with the proteasome via binding of its C-terminal KEKE motif to the Cterminus of Rpn13, a proteasomal ubiquitin receptor which ensnares
polyubiquitinated prey for degradation. UCH37 is known to be catalytically
activated upon binding to Rpn13, allowing cleavage of Lys48-linked polyubiquitin
chains from their distal end, an exo-specific deubiquitination. However, free
UCH37 cleaves polyubiquitin poorly and is believed to be autoinhibited by its C-

xii
terminal UCHL5-like domain, or ULD, which may also be responsible for its
oligomerization in solution. This work examines the structural, biophysical, and
catalytic characteristics of UCH37 in order to elucidate its mechanism of
activation by Rpn13, assess its biophysical assembly with Rpn13 within the
greater proteasomal context, and ascertain its mechanism of exo-specificity
despite the proteasome’s processing of a variety of polyubiquitinated substrates.
To this end, a 1.7 Å resolution X-ray crystal structure was solved of the
catalytic domain of a UCH37 homolog from Trichinella spiralis in complex with
ubiquitin vinyl methyl ester (UbVME), a suicide inhibitor substrate. Our structure,
in combination with another solved of a longer construct of TsUCH37 in complex
with UbVME, provided structural insights into the ability of UCH37 to process
polyubiquitin, namely that its C-terminal UCHL5-like domain (ULD) is responsible
for its exo-specific activity due to a network of interactions with ubiquitin’s Lys48.
Through biophysical and kinetic characterization, we have affirmed the
poor activity of UCH37 alone, but do not ascribe it to autoinhibition because it
does not oligomerize as previously thought, rather we find that it sediments in a
monomer-dimer equilibrium in analytical ultracentrifugation experiments. We
have characterized its binding and activation by Rpn13, finding that UCH37 binds
to Rpn13 with a 22 nM dissociation constant and that mutations to UCH37’s ULD
render it unable to be activated by Rpn13. Interestingly, we have found that while
Rpn13 activates UCH37 for ubiquitin-AMC cleavage, a monoubiquitin fluorogenic
substrate, it appears to slow the enzyme’s processing of Lys48-linked
polyubiquitin chains in our assays.

xiii
Altogether, we have confirmed that UCH37 exists primarily as a monomer
which binds tightly to its proteasomal subunit, Rpn13, and can exo-specifically
cleave Lys48-linked polyubiquitin chains. However, UCH37 may not be activated
as was previously thought, by Rpn13 alone, and likely requires full association
with the 26S proteasome.

1

CHAPTER 1: INTRODUCTION

1.1 Ubiquitination
Ubiquitination occurs through a coordinated enzymatic cascade ending in
the attachment of ubiquitin’s C-terminal glycine (Gly76) to an acceptor lysine
residue via an isopeptide bond. This is achieved through sequential ubiquitin
activation (E1 enzymes), conjugation (E2 enzymes), and ligation (E3 enzymes).
The E1 enzyme, of which there are only two in humans, binds both ubiquitin and
ATP-Mg2+, forms an adenylated ubiquitin intermediate, and then its catalytic
cysteine attacks this adenylated ubiquitin to form a ubiquitin-charged E1,
connected by a high energy thioester bond 1. Ubiquitin is then passed on to one
of about 40 E2 enzymes by attack of their catalytic cysteine to form a charged E2
2

. Subsequently, the charged E2 binds to one of hundreds of E3 enzymes, which

then permits ubiquitin ligation onto a target protein either through direct transfer
from the E2 onto the substrate, or by E2 hand-off to the E3 enzyme, which itself
ligates the ubiquitin onto an acceptor lysine (Fig. 1.1) 2. The determinant of either
of these two mechanisms is inherent in the E3 enzyme; RING/U-box ligases
mediate direct E2 transfer, while HECT ligases form a thioester with ubiquitin and
transfer it themselves. RBR ligases (RING in-between RING) act by combining
both

2
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4
and DNA damage repair. Ubiquitin can also be linked through its start methionine
to form linear ubiquitin chains, which are involved in NF-κB activation as well as
cell death

10

. Additionally, monoubiquitination serves as a signal for a variety of

cellular events, notably transcriptional regulation and degradation of membrane
proteins

11-13

. Currently, little is known about the biological function of chains

linked through K6, K27, K29, and K33

14

. Adding further complexity to the

system, ubiquitin chains can be heterotypic, either through mixed ubiquitin chain
linkages that may be “branched” (mixed chain type) or “forked” (two ubiquitin
chains stemming from one monomer) chains, or as mixed ubiquitin-SUMO
chains, all of which are in their early stages of biological characterization

9,15-17

.

The mechanisms by which E2s and E3s recognize, bind, initiate, and elongate
ubiquitin chains of varying topologies is still under investigation, as well as
identification of their specific substrates.

1.2 Deubiquitination
In opposition to ubiquitination lies deubiquitination, the hydrolysis of the
isopeptide bond (or Met1-linked amide bonds in linear polyubiquitin) and
subsequent release of ubiquitin from its substrate (Fig. 1.1). This is achieved by a
~100-membered group of enzymes called deubiquitinases, or DUBs. They are
further broken down into mechanistic families, the cysteine proteases and the
metallo-proteases. Cysteine DUBs hydrolyze isopeptide bonds utilizing catalytic
Cys, His, and Asp triads, as well as an oxyanion-stabilizing Gln residue. Metallo-

5
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polyubiquitin chains. Other DUBs have specificity for the substrate which has
been ubiquitinated. DUBs that are responsible for chain cleavage have further
specificity for the directionality of their cleavage activity: some remove whole
chains from the site of attachment to a substrate, called en bloc cleavage; some
cleave in the middle of a chain, or endo specificity; and the third group cleaves
from the furthest end of the chain (distal monomer) and removes monomers
sequentially, exo-specific cleavage (Fig. 1.3) 18.
In addition to their DUB domains, many deubiquitinases contain ubiquitin
binding domains (UBDs) which either provide additional stabilization to ubiquitin
binding or confer specificity. Typically, these domains bind monoubiquitin,
sometimes polyubiquitin, with weak affinity in the high micromolar range. They
are most efficient at improving ubiquitin binding when multiple UBDs are found in
one DUB, or if a DUB within a larger complex binds to other proteins containing
UBDs

18,19

. Examples of some of the most frequently-occurring UBDs are UBAs

(ubiquitin associated domains), UIMs (ubiquitin interacting motifs), and ZnFs
(zinc finger ubiquitin binding domains)

19

. UBDs are crucial for the activity of

many deubiquitinases and are also critical regulators of ubiquitin binding across
the entire proteome.

7
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C-terminal extension was named the ULD, or UCHL5-like domain, which is
believed to autoinhibit the enzyme’s catalytic activity. At the end lies its KEKE
motif, a region responsible for its binding to the 26S proteasome through the
proteasomal subunit Rpn13, which has a complementary KEKE motif of its own
21,22,31,32

. BAP1 has a putative ULD domain, by sequence similarity, which has yet

to be characterized

24,33

. BAP1 additionally has a nuclear localization signal at its

far C-terminal end responsible for its cellular localization

24

. Both UCH37 and

BAP1 are known to process larger substrates than UCHL1 and UCHL3; UCH37
disassembles polyubiquitin chains at the 26S proteasome, while BAP1
deubiquitinates histone H2A as part of the Polycomb repressor DUB complex
(PR-DUB)

25,26,34,35

. UCH37 has been found within the assembly of another

macromolecular complex, the Ino80 chromatin remodeling complex, where it
exists in a generally inactive form, the role of which has yet to be explored

36

.

This study focuses on the activity of UCH37, especially as it relates to its role at
the 26S proteasome.

1.3 The 26S Proteasome
The 26S proteasome is a 2.5 MDa proteolytic machine responsible for
degrading the majority of cellular proteins

37-39

. It consists of a 20S core particle

composed of proteolytic enzymes and a 19S regulatory particle responsible for
capturing and feeding ubiquitinated proteins into the mouth of the 20S. The 20S
is made up of 4 stacked heptameric rings of structurally similar, but not identical,
subunits 39-42. The external rings contain seven α subunits while the internal rings

9
contain seve
en β subun
nits. The ex
xternal α su
ubunits act as the gated channel into
he proteolytic chambe
er, where β subunits u
utilize their caspase-likke (β1), trypsinth
lik
ke (β2), and chymotry
ypsin-like (β
β5) activitie
es to cleave
e proteins a
at a wide va
ariety
of sequence
e sites

39

. The three β-subunit proteases all rely on
n an N-term
minal

th
hreonine fo
or catalytic activity

39,,43

. Passag
ge of prote
eins through
h this cham
mber

ensures clea
avage into small peptides, provid
ded they ca
an enter. En
ntry is regulated
bunits; the “closed”
“
form of the ch
hannel is on
nly 9 Å wide
e, only allow
wing
by the α sub

Figure
F
1.5: Structure of the 26S
S proteaso
ome. The 1
19S regula
atory particcle is
highlighted in
i blue, 20S core parrticle in yelllow, AAA A
ATPases in
n purple, Rp
pn11
deubiquitina
ase in red,, and ubiq
quitin recep
ptors Rpn1
10 and Rp
pn13 in grreen.
Adapted
A
from
m PDB ID 4CR2.
4

10
entry by sma
aller peptides, rather than
t
entire globular prroteins 44. W
When conve
erted
o the “open
n” form at ~20
~ Å wide
e, the core particle acccommodattes an unfo
olded
to
polypeptide chain (Fig. 1.6)

44

. This
T
openin
ng is facilita
ated by docking of th
he C-

te
ermini of Rpts 2, 3, an
nd 5 of the 19S AAA ATPases into the binding pocke
ets of
th
he 20S α su
ubunits 42,455-51.
In ord
der to trans
slocate thro
ough the po
ore of the 2
20S core p
particle, pro
oteins
must
m
be unfolded into
o a linear polypeptide
p
e chain; the
ere is some debate a
as to
whether
w
un
nfolding an
nd transloc
cation are sequentia
al, howeve
er evidencce is
mounting
m
to support the
e theory tha
at unfolding
g is coupled
d to transloccation. Thiss

Figure
F
1.6: Structure of the 20
0S and A
AAA ATPasses. The 2
20S has b
been
crystallized in an ope
en and clos
sed gate ((left) and tthe heteroh
hexameric AAA
ATPases,
A
Rpts
R
1-6, are
e shown att right. Ada pted from P
PDB ID 4C
CR2, 1G0U,, and
1RYP.

11
event is achieved by the 19S regulatory particle’s AAA ATPase subunits, Rpts 16, a heterohexameric motor which utilizes ATP hydrolysis to pull polypeptide
chains into the 20S (Fig. 1.6). These Rpts dock to the outer α rings of the 20S
and serve as the base of the 19S RP. Studies of other AAA unfoldases,
especially ClpXP, a bacterial unfoldase, has suggested that translocation and
unfolding are simultaneously achieved through bursts of mechanical force

52,53

.

Both ClpXP and the φ29 DNA packaging motor have been shown to exist 90% of
the time in a dwell state, with only 10% of its time spent in a burst of activity

53,54

.

This has yet to be confirmed in the 26S Rpts, but cryoEM structures of the Rpts
engaged and disengaged with substrate suggest this may be the case 48-50,55,56.
In addition to Rpts 1-6, the base of the 19S regulatory particle contains
two scaffolding proteins, Rpn1 and Rpn2, as well as the two constitutive ubiquitin
receptors, Rpn10 and Rpn13

39,57

. Rpn1 and Rpn2 act to recruit associated

proteins and shuttle factors to the 19S. Through interactions with Ubl (ubiquitinlike) domains, Rpn1 acts as a docking site for shuttle factors which bring
polyubiquitinated proteins to the proteasome, such as Rad23B and Dsk2

58-61

.

Rpn1 is also responsible for recruitment of one of the proteasome’s associated
deubiquitinating enzymes, USP14, discussed below. Thus far, Rpn2 is only
known to anchor one of the intrinsic proteasomal ubiquitin receptors, Rpn13, to
the proteasome, no other shuttle factors or associating ubiquitin receptors 57,61-64.
Rpn10 and Rpn13 are the intrinsic ubiquitin receptors at the proteasome,
although shuttle factors and some temporarily-associating ubiquitin receptors
(Rad23B, Dsk2, Dss1, Ddi1, AIRAP) also bind polyubiquitin and transport it to the

12
proteasome

58,65,66

. Interestingly, deletion of these receptors and shuttle factors

(currently known ones) does not impair growth of yeast

60,64

. Rpn10 and Rpn13

bind tightly to the proteasome, whereas the other shuttle factors bind weakly and
transiently 61,63. It is possible that there are even more shuttle factors or receptors
to be discovered that may rescue protein degradation upon deletion of this set.
Rpn10, or S5a in humans, utilizes two ubiquitin interacting motifs (UIMs) to bind
polyubiquitin avidly and can also recruit the shuttle factor Rad23B 57,58,67-72. It has
an additional N-terminal von Willebrand A (VWA) domain of unknown function.
Rpn13 contains an N-terminal pleckstrin homology domain referred to as the
pleckstrin-like receptor for ubiquitin (Pru) domain, which binds ubiquitin in a novel
mode compared to other ubiquitin binding domains

21-23,62-64

. Rpn13’s C-terminal

domain is responsible for binding UCH37, the second proteasome-associated
deubiquitinase. Rpn10 and Rpn13 lie on the outer edge of the 19S, at opposite
ends, affording polyubiquitin chains a broad surface area for binding as well as
the flexibility of multiple conformations and chain branching (Fig. 1.5) 50,56,57.
Wrapping around and above the 19S base complex lies its lid complex,
one of the least understood components of the 26S. Functions have not been
assigned for its 9 subunits except Rpn11, the proteasome’s constitutive
deubiquitinase. Rpns 3, 5, 6, 7, 9, and 12 contain a proteasome cyclosome
initiation factor (PCI) domain, but the function of these proteins is currently
unknown, aside from acting as scaffolds for other components

73

. Rpn11, a

JAMM metallo-DUB, requires dimerization with Rpn8, which contains an inactive
MPN domain, to form its active deubiquitinating module

55,74-80

. The lid sits above

13
and around the opening pore of the AAA ATPases, with Rpn11 poised
immediately adjacent to the access point of polyubiquitinated substrates 50,55.

1.3.1 Deubiquitination at the 26S Proteasome
After polyubiquitinated proteins are brought to the 26S proteasome via
shuttle factors and transient ubiquitin receptors, they bind to the proteasome’s
intrinsic ubiquitin receptors, Rpn13 and Rpn1021,23,57,58,62,81. As substrates are
unfolded and translocated into the interior of the core particle, the metallodeubiquitinase, Rpn11, cleaves off whole ubiquitin chains from the substrate
protein, releasing them back into the cellular pool of ubiquitin

32,75-77

. Rpn11

utilizes a catalytic zinc ion bound by two histidines and an aspartate to cleave
polyubiquitin chains in an en bloc fashion, that is, the entire chain is removed
from its acceptor lysine on a substrate protein74,79. From cryo-EM structures of
the 26S engaged and free of ubiquitinated substrates, it is known that Rpn11
initially exists in an occluded state that is misaligned with the central pore and
ATPases, which subsequently undergoes a dramatic conformational change
upon substrate binding and engagement

50,55

. This conformational change aligns

the active site of Rpn11 immediately above the central pore and ATPase ring
opening, which then allows it to cleave entire polyubiquitin chains from an
engaged substrate protein

50,55

. Rpn11 is a highly promiscuous DUB capable of

cleaving many different chain types and possibly having endopeptidase activity

14
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. Both
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UCH37 and USP14 are cysteine protease DUBs which cleave polyubiquitin
chains exo-specifically, that is from the furthest monomer (distal) from the
substrate protein and working their way inwards. USP14 associates with the
proteasome through its Ubl domain, which binds to Rpn1, a known docking point
for other Ubl domain-containing proteins. UCH37, however, binds to an ubiquitin
receptor, Rpn13, through matching KEKE motifs within both of their C-terminal
domains. USP14 and UCH37 have poor basal levels of deubiquitinase activity
alone, but become significantly activated upon recruitment to the 26S
proteasome21,78,84,87,88.

They

are

generally

thought

to

be

present

in

substoichiometric amounts at the 26S, especially USP14 due to the fact that its
binding partner, Rpn1, is known to bind to multiple proteins at that same site.
Currently it is believed that UCH37 is specific for Lys48-linked chains and that
USP14 may process other chain types, however, the variety of ubiquitinated
species brought to the proteasome indicates that these DUBs are probably more
promiscuous than first thought.
A few theories exist as to what role these associated DUBs play in
proteasome degradation: (1) they recycle monoubiquitin, for further use by the
cell

89,90

; (2) they may allow dissociation of chains prior to substrate commitment

for degradation, and in turn rescue a small portion of proteins slated for
degradation that may be inappropriately labeled

34,35

; or (3) after a polyubiquitin

chain has been freed from its substrate by Rpn11, the two associated DUBs
sequentially remove ubiquitin monomers until the affinity of the polyubiquitin
chain for Rpn10 or Rpn13 is poor enough to dissociate from the 26S, allowing

16
“resetting” of the proteasome for another round of degradation

39,91

. Their

inhibition has been shown to accelerate proteasomal degradation, however,
further work is needed to clarify the biological role of proteasome-associated
deubiquitination 86,92.
Within this work, we present the X-ray crystal structure of a UCH37
homolog bound to ubiquitin, as well as biophysical and kinetic data, which
provides a better structural understanding of the specificity and activation of this
proteasome-bound

DUB.

Despite

the

broad

spectrum

of

ubiquitinated

proteasomal substrates, this DUB appears to maintain a limited specificity. We
hope that these studies of UCH37 will obtain a better picture of how
deubiquitinating enzymes in general balance a need for specificity in the face of a
plethora of ubiquitinated proteins, as well as how these enzymes are kept in
inactive/active states by cellular protein partners.
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CHAPTER 2: STRUCTURE OF TSUCH37CAT-UBVME

2.1 Introduction
Structural

approaches

to

studying

ubiquitination/deubiquitination

machinery has yielded extensive information about its detailed mechanisms,
providing vital understanding of these proteins’ ability to recognize either highly
specific chain types or to be grossly promiscuous for any ubiquitinated molecule
available. This approach has given the field incredible insight into the biological
significance of ubiquitination. The structures of many deubiquitinases have been
solved alone and in complex with ubiquitin or a ubiquitin variant. Generally, DUBs
bind monoubiquitin quite poorly, especially if they act as polyubiquitin chain
trimmers in cells. Therefore, in order to capture a DUB-ubiquitin bound state,
covalent linkage of monoubiquitin is required, to prevent dissociation during
crystallography. For this end, a handful of suicide inhibitor ubiquitin variants are
used in structural biology. One of these is ubiquitin vinyl methyl ester (UbVME),
used in this study, which seems to have the highest reactivity with UCH family
DUBs. Here, I have solved the X-ray crystal structure of a UCH37 homolog from
Trichinella spiralis in complex with ubiquitin vinyl methyl ester. This structure
highlights the similarities of UCH-family DUB binding to ubiquitin, as many
contacts are conserved with UCHL1 and UCHL3. However, the active site
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crossover loop, a structural feature common to UCH enzymes, is not resolved in
the TsUCH37cat-UbVME structure due to a high amount of flexibility that is not
abrogated upon ubiquitin binding, an unexpected result that hints at UCH37’s
mechanism of activation.

2.2 Materials and Methods

2.2.1 Synthesis of Ubiquitin Vinyl Methyl Ester
The synthesis of glycine vinyl methyl ester (GlyVME) has been previously
published, but was modified in our hands (Fig 2.1)

1-3

. For the Boc protection

reaction, 8 grams (88 mmol) of 3-amino-1,2-propanediol was dissolved in 150 mL
water, then cooled on ice in order to add 23 grams (105 mmol) of di-tert-butyl
dicarbonate (Boc anhydride), after which the reaction was returned to room
temperature. Then the reaction was brought to pH 10.5 by addition of sodium
hydroxide and the reaction was allowed to run overnight at room temperature.
The reaction was diluted with 100 mL of ethyl acetate, cooled on ice, and then
brought to pH 2.5 with hydrochloric acid. The product was then extracted out with
8 x 50 mL ethyl acetate. The organic layer was washed with NaHSO4 and brine,
dried over sodium sulfate, and then rotovapped down and stored at -20 C. For
the oxidation reaction, 7-8 g of Boc-propanediol was dissolved in 125 mL water,
to which 1.4 molar equivalents of NaIO4 were added. The reaction was stirred for
2-12 hours. The product was extracted out with 3 x 100 mL ethyl acetate, dried
over sodium sulfate, and then rotovapped down. The aldehyde product was used
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within a day and stored at -20 C. For the Horner Wadsworth Emmons reaction, 1
equivalent of sodium hydride (60% suspension in mineral oil) was added to a
flame-dried round bottom and immediately suspended in 40 mL dry THF, then
purged with N2. The sodium hydride was washed 3 x 30 mL dry THF and then 1
equivalent of trimethyl phosphonoacetate was added over 1 hr on ice. Additional
THF was added as needed to keep the reaction in solution. The Boc-aldehyde
was dissolved in minimal THF and added to the reaction over 1 hr on ice. After
addition, the reaction was allowed to warm to room temperature and run from 612 hrs. The reaction was quenched with 200 mL water and then THF was
removed by rotovapping. The product, Boc-GlyVME, was extracted out with 3 x
50 mL chloroform and the organic layer was washed once with 50 mL of 2%
hydrochloric acid and once with 50 mL saturated sodium carbonate. The organic
layer was dried over sodium sulfate and then rotovapped down and stored until
purification. Boc-GlyVME was purified by silica flash chromatography using a
gradient of 0-20% ethyl acetate in hexanes, pooling only fractions containing the
E isomer. Solvent was rotovapped off, the product was washed 2 x with DCM,
and then rotovapped down again. For Boc deprotection and crystallization of the
final product, 2 molar equivalents of p-toluenesulfonic acid was dissolved in 100200 mL diethyl ether, dried over sodium sulfate, and decanted off. Boc-GlyVME
was dissolved in minimal ether and added to the pTSA solution. GlyVME tosyl
salt crystallized out overnight, was filtered out, and stored at -20 C until reaction
with UbMESNa.
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the column to displace Ub1-75 from the intein group by incubating overnight at
37°C. The eluate was collected and concentrated down to 1.5 mL.
In order to generate UbVME, UbMESNa was incubated with 200 mg
GlyVME and 125 mg NHS dissolved in 1 M NaHCO3 at pH 8 overnight at room
temperature. After incubation, UbVME was dialyzed into 50 mM NaOAc pH 4.5
for 4 hours, then applied to a Mono S cation exchange column for purification
from UbMESNa or hydrolyzed Ub1-75. Fractions were tested for reactivity with
UCHL3 and the most reactive fractions were pooled, concentrated down, and
flash frozen and stored at -80°C.

2.2.2 Cloning, Expression, and Protein Purification of TsUCH37cat
Full-length Trichinella spiralis (Ts) UCH37 in the pET28a vector was sent
from the lab of Katerina Artavanis-Tsakonas, who had previously identified the
enzyme as a UCH family member and confirmed it to be UCH37 by coimmunoprecipitations and pull-downs of proteasomal subunits

4

. Following

standard cloning protocols, the catalytic domain of TsUCH37, residues 1-226,
was subcloned into the pGEX 6P1 vector between BamHI and XhoI digestion
sites. The protein was expressed in E. coli Rosetta DE3 cells to an O.D. of 1.0
and the cells were harvested after expression overnight at 18°C. Cells were lysed
by French press and spun down at 100,000 x g for 1 hour. The supernatant was
applied to glutathione sepharose beads and unbound proteins were washed off
with column buffer (1 x PBS, 400 mM KCl). GST-fused TsUCH37cat was eluted
with reduced glutathione and incubated with PreScission Protease (GE
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Biosciences) overnight at 4°C. TsUCH37cat was run back over the glutathione
beads to capture GST, and then the pure protein was concentrated down and run
on a HiLoad Superdex 75 for further purification. Pure fractions were
concentrated down, flash frozen, and stored at -80°C.

2.2.3 Complexation of TsUCH37cat with UbVME
Test reactions to complex TsUCH37cat with UbVME were set up in 12 uL
scale to determine the ideal concentration to push complexation to completion.
Three tests were done at 37°C for 3 hours at 29 mg/mL, 14.4 mg/mL, and 9.6
mg/mL TsUCH37cat (Fig. 2.2). For the final scale up reaction, 14.4 mg/mL was
chosen. The scale-up reaction was composed of 600 uL of 14.4 mg/mL
TsUCH37cat, 600 uL UbVME, and 70 uL 1M Tris pH 8.0, for a total volume of 1.9
mL (Fig. 2.2). After 3 hours at 37°C, the reaction was diluted to 4 mL and run on
a Superdex 75 for further purification, but an unexpected higher molecular weight
species was not purified, so all fractions from this step were pooled, buffer
exchanged, and run on a MonoQ anion exchange column in 0-40% 50 mM Tris
pH 7.6, 1 M NaCl, 1 mM DTT over 45 column volumes. The pure complex eluted
at 17% 1 M NaCl (Fig. 2.2). Pure fractions were pooled, concentrated down to 35 mg/mL, flash frozen, and stored at -80°C.
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that each buffer was supplemented with 2-5 mM DTT to keep selenomethionine
in a reducing environment. Mass spectrometry of SeMet TsUCH37cat by protein
MALDI confirmed that all four methionines in the protein were enriched with
SeMet, an M+1 molecular weight of 26238.6 Da and M+2 of 13117.1 Da, with a
calculated molecular weight of 26238 Da. SeMet TsUCH37cat was complexed
with UbVME and purified by MonoQ anion exchange chromatography. Pure
fractions were pooled, concentrated down, and flash frozen and stored at -80°C.
Yields for the SeMet protein were reduced; therefore the SeMet complex was
lower concentration than the original complex.

2.2.5 Crystallization and Structure Solution
Native TsUCH37cat-UbVME was screened at 3 mg/mL in ~700
crystallographic conditions by sitting drop vapor diffusion. A hit was identified in
the Hampton Research Ammonium Sulfate grid screen, composed of 3 M
ammonium sulfate, 0.1 M bicine pH 9 at room temperature after 2 days by
hanging drop vapor diffusion. However, rather than single, 3D crystals, the initial
hit appeared to be stacks of 2D plate crystals. In anticipation of poor data due to
multi-latticed crystals, the initial hit was optimized by additive screening. Single
3D crystals appeared with the addition of 2 mM glutathione (mixture of oxidized
and reduced). Crystallization attempts with the SeMet complex in the same
mother liquor composition as the native hit did not yield any crystals, therefore
microseeding with native crystals was done to induce SeMet complex
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The initial model was obtained from the Phenix AutoSol wizard using
selenium SAD phases with an input of 8 Se sites (from Matthews coefficient,
determined to be a dimer in the asymmetric unit). The initial model was given a
FOM (figure of merit) of 0.338, and initial Rwork of 0.3695 and Rfree of 0.3884. Its
sequence was built in using the Phenix AutoBuild wizard with additional manual
model building in Coot

7,8

. Two copies of the complex were found in the

asymmetric unit, having a space group of C2. Refinement of the structure was
done in Phenix using some TLS refinement (entire asymmetric unit considered to
be one TLS group) and optimized weighting for stereochemical restraints 7.
Overall completeness of the data was poor, at 88.5%, but this can be credited to
poor completeness in the highest resolution shells (42%), which did not prevent
structure solution or refinement. The final model had an R factor of 17.4% and an
Rfree of 21% with <0.2% of residues in the disallowed region of the
Ramachandran plot and scoring a 98% in assessment by Molprobity 9. The
structure was deposited in the Protein Databank (PDB) under the entry 4I6N 10.
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2.3 Results

2.3.1 Structure of TsUCH37cat-UbVME
TsUCH37cat-UbVME crystallized in the C2 space group with two copies of
the complex in the asymmetric unit. The final model had an R factor of 17.4%
and an Rfree of 21% (Table 2.1).
The first structural element to come to our attention was the presence of
electron density for a disulfide bond between Cys71 of each TsUCH37cat
monomer, leading to disulfide-mediated dimerization in the asymmetric unit.
Human UCH37 was previously thought to oligomerize in solution through its Cterminal domain, therefore this result was unexpected. In order to determine if
this dimerization has biological relevance, the TsUCH37cat-UbVME complex and
TsUCH37cat alone were both subjected to analytical ultracentrifugation, the
results of which are discussed in Section 3.3. We concluded that this disulfide
bond formation was a crystallographic artifact rather than a biologically significant
event. It likely arose as a result of the introduction of glutathione as an additive
and may have assisted crystal packing into a better form than the initial 2D plate
crystals. The two copies of the complex have an RMSD of 0.39, indicating very
few differences between them. Analysis of the complex, for the purpose of this
document, will focus on Chains A and B in the PDB file rather than the copy,
Chains C and D.
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of the tail as well as Arg72 and Arg74’s side chains. The active site tetrad,
composed of Cys85, Asp176, His161, and the oxyanion-stabilizing residue
Gln79, is arranged in a canonical orientation for the UCH family, which is seen in
papain-like cysteine proteases as well. The catalytic Cys85 of TsUCH37 has
flipped about 90° compared to Cys88 of the unbound human enzyme (PDB
3IHR) upon binding to GlyVME, a mimic of the acyl-enzyme intermediate during
catalysis. This phenomenon is also seen in the ubiquitin-bound and unbound
structures of UCHL1, and is believed to be a conformational switch from an
unproductive form of the enzyme that may exist as a protective mechanism

12

.

Some deubiquitinases operate within an oxidative environment, and this
conformational change may protect the enzyme against cysteine oxidation 14.

2.3.3 Distal Site Binding
Stabilization of ubiquitin’s C-terminal tail is the primary mode of ubiquitin
binding by UCH family enzymes, with the second-most important being its distal
site interactions with ubiquitin’s Leu8, Thr7, and Thr9 as well as ubiquitin’s Ile44
patch. Ubiquitin-interacting residues from the Ts to human UCH37 are not highly
conserved compared to its catalytic cleft residues. The distal site of TsUCH37
utilizes different hydrophobic groups than the human enzyme for ubiquitin
binding, such as replacement of Ser37 with Leu36 and substitution of the large
Trp36 with Val34 and Val35 (Fig 2.6). Additionally, comparing the distal pockets
of the human unbound enzyme versus bound TsUCH37, there appears to be a
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make any contacts with ubiquitin in the situation of this complex: UCH37 –
monoubiquitin. This leads one to believe that an additional protein binding event
would be required to stabilize the crossover loop, that it may require a different
minimal substrate (diubiquitin, triubiquitin, etc) or that the crossover loop binds to
another protein regulator. We speculate that this other protein may be Rpn13,
and that this binding event may be the source of activation of UCH37’s catalytic
activity.

2.4 Discussion
Here we have presented the structure of TsUCH37cat bound to ubiquitin
vinyl methyl ester, which has provided some valuable insights into the
mechanism of this UCH family deubiquitinase. The enzyme relies on a complex
network of interactions around ubiquitin’s C-terminal tail for substrate
stabilization, which is highly conserved between TsUCH37 and the other yeast
and human homologs of UCH enzymes. Additionally, TsUCH37 utilizes distal site
binding to recognize ubiquitin’s Ile44 patch and Leu8-Thr9 motif. However, the
residues responsible for distal site binding are not as conserved as those in the
catalytic cleft, compared to human UCH37. This lack of conservation may impact
the affinity of ubiquitin binding, which will be explored in Part 2 through
comparison of the enzyme’s catalytic activity compared to the human enzyme.
This region of the enzyme may confer selectivity among UCH family enzymes,
distinguishing each from one another, as their catalytic clefts are nearly identical.
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The most significant structural difference between TsUCH37cat and the
other UCH family structures is that its crossover loop has not gained sufficient
stabilization upon ubiquitin binding to be visualized in its X-ray crystal structure.
The crossover loop is a structural element of UCH enzymes which is responsible
for substrate filtering and binding, which appears to not play a role in ubiquitin
binding for TsUCH37, and likely human UCH37 as well. We speculate that the
crossover loop would be resolved in the structure if it was satisfying all its
necessary contacts, which probably requires binding to an additional partner. We
further hypothesize that this binding partner may be Rpn13, the proteasomal
subunit which anchors UCH37 to the 26S proteasome. It seems therefore that
the crossover loop in UCH37 may be a key element in the regulation of UCH37’s
catalytic activity through protein-protein contacts. Further examination of the
crossover loop in binding studies should confirm our hypothesis.
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CHAPTER 3: KINETIC AND BIOPHYSICAL CHARACTERIZATION OF
TSUCH37

3.1 Introduction
The biophysical characteristics of UCH37 keenly regulate its kinetic
activity as well as biological association with its proteasomal binding partner,
Rpn13. Its ULD, or UCHL5-like domain, has been shown to alter its activity and
ability to bind to the 26S proteasome. Within this ULD lies the KEKE motif, a
region spanning the final 20-30 amino acids of the protein, which is responsible
for its binding to the proteasomal subunit Rpn13. Rpn13 harbors a
complementary C-terminal KEKE motif, which binds to UCH37 (Fig 3.1).
Interestingly, the ULD of UCH37 is also thought to play two additional roles within
the enzyme: (1) regulation of its oligomeric state and (2) autoinhibition of the
enzyme’s catalysis1-5. The oligomerization of UCH37 was explained by
tetramerization of the human enzyme in its X-ray crystal structure (PDB ID 3IHR)
as well as in-solution higher order oligomers observed during size-exclusion
chromatography (Fig 3.2) 5. Autoinhibition has been seen by multiple groups in
the context of purified protein, by deletion of the ULD and comparison of its
activity versus that of the full-length enzyme against ubiquitin 7-amino-4methylcoumarin, a fluorogenic monoubiquitin substrate standard in the DUB field,
but limited in that it does not address the processing of polyubiquitin

1,2,5-9

.
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characteristics of the event, we are still unclear about how the enzyme transitions
between its basal and activated states.

3.2 Materials and Methods

3.2.1 Cloning, Expression, and Protein Purification
TsUCH37cat

and

TsUCH37cat-UbVME

were

purified

as

described

previously in Part 2.2.2. TsUCH37FL with an N-terminal 6xHis tag in pET28a+
was expressed in E. coli by Dr. Myung-Il Kim as described in Morrow et. al, 2013
10

. For isothermal titration calorimetry, human Rpn13 was expressed and purified

by Dr. Judith Ronau from E. coli on glutathione beads and subsequently by size
exclusion chromatography. Human UCH37 proteins used for isothermal titration
calorimetry were wild-type and an E284A mutant (discussed further in Section
4.3.2), both expressed from a pET28a+ plasmid in E. coli, purified on Ni-NTA
beads using a 50 – 500 mM imidazole gradient (purification buffer of 20 mM
sodium phosphate pH 7.0, 300 mM NaCl, ). Due to an engineered HRV 3C
protease site, Prescission Protease (GE Biosciences) was added to remove the
6xHis tag and linker, which was subsequently removed by incubation with
glutathione beads. Second step purification was done on both wild-type and
UCH37 E284A on a Sephadex S200 size exclusion column (GE Biosciences)
and pure fractions were pooled, concentrated down, and flash frozen as aliquots.
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3.2.2 Analytical Ultracentrifugation
TsUCH37cat and TsUCH37cat-UbVME were both dialyzed extensively
against 50 mM Tris pH 7.4, 200 mM NaCl, and 1 mM DTT. Samples were run at
concentrations a range of concentrations: 8, 16, and 32 µM for TsUCH37cat and
10, 18, and 31 µM for TsUCH37cat-UbVME to determine oligomeric states at high
concentrations. Samples were run on a Beckman-Coulter XLA analytical
ultracentrifuge at 50,000 rpm and monitored at 280 nm for 150 scans.
Sedimentation coefficient distributions were analyzed by SEDFIT (v. 13.0b) 11.
For analysis of human UCH37 and Rpn13, proteins were both extensively
dialyzed against 50 mM Tris pH 7.5, 50 mM NaCl, 1 mM TCEP. For analysis of
individual oligomerization states, UCH37 was run at 8, 16, and 32 µM and Rpn13
was run at 13.5, 27, and 54 µM. Analysis of the UCH37-Rpn13 complex was run
at concentrations of 4 and 8 µM, 4 and 16 µM, and 4 and 32 µM of UCH37 and
Rpn13, respectively. Samples were run and analyzed by the same methods as
TsUCH37cat and TsUCH37cat-UbVME, above.

3.2.3 Ubiquitin-AMC Hydrolysis
Cleavage

of

7-amino-4-methylcoumarin

from

the

C-terminus

of

monoubiquitin, or UbAMC cleavage, was monitored in a reaction buffer
containing 50 mM Tris pH 7.6, 0.5 mM EDTA, 0.1% bovine serum albumin, and 5
mM DTT. TsUCH37cat and TsUCH37FL were diluted in reaction buffer to 7 nM
final reaction concentration and preincubated at 30°C for 5 minutes prior to the
reaction. Reactions were initiated by addition of UbAMC (Boston Biochem) and
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were measured on a Tecan fluorescence plate reader (Männedorf, Switzerland)
with 380 nm excitation wavelength and 465 nm emission wavelength at 30°C for
1 hr. Progress curves and Michaelis-Menten kinetics were plotted and fit in
SigmaPlot (Systat Software).

3.2.4 Isothermal Titration Calorimetry
For isothermal titration calorimetry, wild-type UCH37, UCH37 E284A, and
Rpn13 were dialyzed extensively together against 50 mM Tris pH 7.5, 50 mM
NaCl, 1 mM TCEP. ITC experiments were done using a MicroCal ITC200 (GE
Biosciences). For determination of the Kd of UCH37 wild-type and Rpn13
binding, two experiments were averaged together: 20 µM UCH37 in the cell with
228 µM Rpn13 injected, and 10 µM UCH37 in the cell with 100 µM Rpn13
injected. For UCH37 E284A, 10 µM E284A was in the cell and 100 µM Rpn13
was injected. The data was analyzed and fit to a single binding site model in
SEDPHAT 11.
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At concentrations higher than that in cells (8 – 32 µM), neither TsUCH37cat nor
the TsUCH37cat-UbVME complex were found to exist in solution as dimers. Both
are monomeric, with sedimentation coefficients (S20,w) of 3.3 for the complex and
2.8 for the catalytic domain (Fig. 3.3). Therefore, the dimerization event observed
in the crystal structure is an artifact of crystal packing, mediated by disulfide bond
formation resulting from oxidative conditions prevailing in the crystallization buffer
(glutathione additive).

3.3.2 Kinetic Characterization of TsUCH37cat and TsUCH37FL
In order to characterize the catalytic activity of TsUCH37, its activity
against a standard DUB substrate, a fluorogenic monoubiquitin derivative called
UbAMC, was assessed. The original goal of studying TsUCH37 previously was
for drug targeting12, therefore, it was of interest to examine its catalytic
mechanism compared to that of human UCH37 and the other UCH family DUBs.
Compared to the catalytic domain of human UCH37, TsUCH37cat has about a 20fold lower KM, indicating an improvement in substrate binding, however, the kcat
was 100-fold lower, yielding an overall 5-fold decrease in efficiency of the
enzyme (Fig 3.4) 9. It would appear that TsUCH37’s catalytic domain binds
substrate tighter, but that may also impair its ability to dissociate product for
another round of catalysis. Not surprisingly, TsUCH37cat’s KM is about 14-fold
higher than UCHL3 and 23-fold higher than that of UCHL1, both of which bind
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3.3.3 Analysis of UCH37 Oligomeric State
In order to probe whether the previously proposed model of UCH37
tetramerization or higher order oligomerization was possible, we examined its
oligomerization by analytical ultracentrifugation (Fig 3.5)

5

. Additionally, the

stoichiometry of the binding of UCH37 to Rpn13, its proteasomal binding partner,
was determined. Analytical ultracentrifugation of UCH37 alone at 8, 16, and 32
µM yielded data indicating that the enzyme primarily exists as a monomer at
lower concentrations, but is capable of a concentration-dependent rapid
monomer-dimer equilibrium, which is seen most prominently in the 32 µM
concentration sample. Higher order oligomers were not detected at that those
concentrations, which does not rule out the possibility, but indicates that at
cellular concentrations, the enzyme is likely monomeric.
As for the UCH37-Rpn13 complex, first the solution state of Rpn13 was
determined alone at 13.5, 27, and 54 µM. Rpn13 primarily exists as a monomer
with a small population of higher order oligomers or aggregates, however this
proportion is quite small. The UCH37-Rpn13 complex was run at three different
concentrations of Rpn13 (8, 16, and 32 µM), but with UCH37 fixed at 4 µM. The
complex exists in a 1:1 stoichiometry, which is not a surprise given that Rpn13
only has one recognition motif for UCH37 to bind. These results do not appear to
support the theory that Rpn13 may relieve UCH37 of its autoinhibition through
binding its ULD to change the oligomeric state of the enzyme. Both proteins are
predominantly monomeric in solution and form a 1:1 complex at the proteasome.
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3.3..4 Analysis of UCH37 Binding to Rpn13
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wild-type, one with 20 µM UCH37 in the cell and 228 µM Rpn13 as the titrant,
and a second with 10 µM UCH37 in the cell and 100 µM Rpn13 as the titrant.
The average Kd was 22 ± 6 nM. UCH37 E284A was only run as a single
experiment, with 10 µM E284A in the cell and 100 µM Rpn13 injected, which
yielded a Kd of 18.5 ± 7 nM. Although UCH37 in cells is known to exist as a
population of free enzyme, not bound to the 26S proteasome and can associate
with the Ino80 chromatin remodeling complex, these dissociation constants
suggest very tight binding between this DUB and its proteasomal anchor, Rpn13
2

. This interaction is known to be abolished upon deletion of UCH37’s KEKE

motif, and it is clear that even though the ULD mutation E284A impairs activation
of the enzyme (Section 4.3.2), the ULD region likely does not contribute
significantly to binding to Rpn13

1,6-8

. Additionally, as the Kd of UCH37-Rpn13

binding is so low, it further disproves the possibility that UCH37 oligomerizes in
cells.

3.4 Discussion
Thorough characterization of UCH37’s kinetic and biophysical properties
is necessary to dissect its cellular association with the 26S proteasome and
potential autoinhibition. These studies have shed more light on the role of its ULD
in catalysis and binding, but more work is still needed to understand its
activation. We have confirmed that dimerization of the TsUCH37cat-UbVME
complex in its crystal structure is a crystallographic artifact of tight packing. Our
studies of the kinetic activities of TsUCH37cat and TsUCH37FL, and our analysis
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USP14, Ubp6, has two possible binding sites on Rpn1, one a tighter 62 nM Kd
site, the other much weaker at nearly 2 µM13. Rpn1 is known to bind to shuttle
factors and other Ubl domain-containing proteins, therefore, USP14 is not always
bound to it. These numbers would suggest that UCH37 is more frequently found
in a proteasomal context than USP14 and may play a more significant biological
role.
However, these investigations still leave open the question of how UCH37
is activated at the proteasome, if it occurs merely through association with a
conformationally-accessible Rpn13, or if another binding partner is required. A
UCH37 mutant, E284A, which could not be activated by Rpn13 during ubiquitinAMC hydrolysis (Section 4.3.2) bound to Rpn13 with nearly the same Kd as the
wild-type enzyme. This mutation isolates Rpn13’s activation of UCH37 to an
event independent of simple binding. Further studies of this mutant in the
presence of di- or tri-ubiquitin, as well as in the presence of Rpn2, the
proteasomal subunit which binds Rpn13’s N-terminus, may provide the key to
UCH37’s mode of activation.
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CHAPTER 4: ANALYSIS OF THE TSUCH37∆C46-UBVME STRUCTURE AND
THE ROLE OF THE ULD

4.1 Introduction
Although the TsUCH37cat-UbVME structure provided valuable insight into
the mechanism of UCH37 and its ability to recognize and bind monoubiquitin, we
are still lacking information about the role of the ULD in catalysis, binding, and
activation. However, another group member, Dr. Myung-Il Kim, was able to
crystallize and solve the structure of a longer construct of TsUCH37 in complex
with UbVME for us to glean information regarding the ULD, hereafter referred to
as TsUCH37∆C46-UbVME (Fig 4.1). Due to cleavage of the protein during
purification, only a portion of the ULD was shown in the structure, but it provided
important clues regarding ubiquitin recognition by the enzyme. Contacts between
the catalytic domain of TsUCH37∆C46 and ubiquitin are identical to that of
TsUCH37cat, including a lack of ordered density for the crossover loop residues.
However, contacts between ubiquitin and the ULD are seen, making this an
additional ubiquitin binding interface. These contacts involve hydrogen bonds
and salt bridge interactions between TsUCH37’s Arg261 and Tyr262 with
ubiquitin’s Gln49 and Lys48, which forces a salt bridge interaction between
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4.2 Materials and Methods

4.2.1 Molecular Dynamics Simulations
A starting model of human UCH37-UbVME was made by modeling of fulllength TsUCH37 using the human UCH37 structure (PDB ID 3IHR) as the search
model in the SwissModel homology modeling server 2. The final 46 residues
missing in the TsUCH37∆C46-UbVME were appended from the homology model
in Coot, which then underwent one round of refinement in Phenix

3,4

. Professor

Markus Lill (Purdue University) then utilized this model for molecular dynamics
simulations, methods described in Morrow et. al, 2013

5

. From the 2 ns

simulation, snapshots were examined for specific residues’ proximities to
ubiquitin. The majority of potential interactions could be seen at the 1.3 ns
snapshot.

4.2.2 Site-directed Mutagenesis and Protein Purification
Based on interactions seen in the MD simulations described above, a list
of Ub-interacting ULD residues were generated from the Ts enzyme and
corresponding residues in the human enzymes were mutated to Ala. Sitedirected mutagenesis was performed using the AccuPower PCR PreMix
(Bioneer) and mutations were confirmed by sequencing. Proteins were
expressed in Rosetta2 DE3 E. coli expression cells and purified by Ni NTA
beads. After cleavage of the 6xHis tag by Prescission Protease (GE
Biosciences), proteins were passed over GSH beads to remove the tag and
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protease. Proteins were further purified by size-exclusion chromatography on a
Superdex 200 HiLoad column (GE Biosciences). Pure fractions were pooled,
concentrated down, and flash frozen as aliquots. Concentrations were
determined by UV/Vis. Human Rpn13FL was provided by Dr. Judith Ronau.

4.2.3 Ubiquitin-AMC Hydrolysis Assays
Cleavage

of

7-amino-4-methylcoumarin

from

the

C-terminus

of

monoubiquitin, or UbAMC cleavage, was monitored in a reaction buffer
containing 50 mM Tris pH 7.6, 0.5 mM EDTA, 0.1% bovine serum albumin, and 5
mM DTT. UCH37 wild-type and mutants were pre-incubated with Rpn13 on ice
for 1 hr, and then diluted in reaction buffer to final reaction concentrations of 0.5
nM and 15 nM, respectively, and warmed to 30°C for 5 minutes prior to the
reaction. Reactions were initiated by addition of UbAMC (Boston Biochem) and
were measured on a Tecan fluorescence plate reader (Männedorf, Switzerland)
with 380 nm excitation wavelength and 465 nm emission wavelength at 30°C for
1 hr. Progress curves were plotted in Kaleidagraph.
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4.2.4 Synthesis of Asymmetric Triubiquitin Substrate and Assays
Site-directed mutagenesis was used to introduce a Gly76Val mutation into
a UbW77 construct in the pGEX-6P-1, which was subsequently confirmed by
sequencing. The double mutant UbG76V

W77

was expressed in Rosetta2 DE3 E.

coli cells and purified on glutathione beads. After treatment with Prescission
Protease (GE Biosciences) to remove its N-terminal GST tag, the protein was run
back over glutathione beads to remove the tag and protease. UbG76V

W77

was

further purified by size exclusion chromatography on a Sephadex 75 HiLoad
column (GE Biosciences) and pure fractions were pooled, concentrated down,
and flash frozen as aliquots.
Untagged ubiquitin in the pRSET vector was expressed in Rosetta2 DE3
E. coli cells, spun down, resuspended in purification buffer A (50 mM sodium
acetate pH 4.5, 2 mM DTT), lysed by French press, heated to 80°C for 10
minutes, then spun down at 30,000xg for 30 minutes. The supernatant was
brought to pH 4.5 by 1N HCl and then was purified by cation exchange
chromatography on SP sepharose beads (GE Biosciences) by gradient elution
with purification buffer B (same as A, but with 1 M NaCl). Pure fractions were
pooled and concentrated down, then further buffer exchanged and purified by
size exclusion chromatography on a Sephadex 75 HiLoad column (GE
Biosciences) into 50 mM Tris pH 7.6, 50 mM NaCl, 1 mM DTT. Pure fractions
were pooled, concentrated down, and flash frozen as aliquots.
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For polyubiquitin cleavage assays, wild-type K48-linked di-, tri-, and tetraubiquitin were generated biosynthetically in the same manner as mutant tri
UbG76V W77. 1.5 µM wild-type or E284A UCH37 was incubated for 1 hour on ice
with 50 µM GST-Rpn13 (for triUbG76V W77 assays) or 5 µM untagged Rpn13 (for
wild-type polyubiquitin assays) in buffer containing 50 mM Tris pH 7.6, 0.5 mM
EDTA, 0.1% bovine serum albumin, and 5 mM DTT. Reactions were started with
the addition of 15 µM triUbG76V

W77

, tetraubiquitin, wild-type triubiquitin, or

diubiquitin and time points were quenched with SDS PAGE buffer. Reactions
were run on 15% SDS PAGE gels and stained with Coomassie.

4.3 Results

4.3.1 Analysis of Molecular Dynamics Simulations
After Professor Markus Lill (Purdue University) generated a 2 ns molecular
dynamics simulation for full-length TsUCH37-UbVME, each frame was analyzed
for potential interactions between the ULD of TsUCH37, the mobile element, and
ubiquitin, which was held stationary. The majority of interactions were seen at a
1.3 ns snapshot, showing potential interactions between many ubiquitin-facing
ULD residues and ubiquitin (Fig. 4.3). Although some interactions are only within
van der Waals or salt bridge distances, some possible hydrogen bonds were also
observed. The majority of the residues at this interface are also highly conserved
from yeast up to human UCH37, therefore, the most conserved residues were
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isothermal titration calorimetry (ITC) to determine the binding affinity of E284A
with Rpn13 compared to wild-type UCH37. The results, shown in Section 3.3.4,
indicate that binding to Rpn13 is not impaired by this mutation as its Kd is close to
that of wild-type UCH37. Therefore, this mutation may specifically inhibit the
mechanism of activation of UCH37 by Rpn13, specifically.
Interestingly, ULD mutations near E284 do not impair activation within the
context of the UbAMC assay, such as R280 and Y281. These two residues are
not as conserved as E284; R280 is substituted with Met, Lys, or Leu, and Y281 is
replaced by Trp in lower organisms. Perhaps these residues are more important
for ubiquitin recognition, rather than activation.

4.3.3 Triubiquitin Cleavage by ULD Mutants
In order to assess directional cleavage by UCH37, an asymmetric
polyubiquitin substrate was needed. To this end, UbW77, a construct utilized for
studies of the activity of UCHL1, was given an additional mutation, Gly76Val, by
site-directed mutagenesis in order to render its Trp77 non-cleavable by UCH37 8.
This double mutant monomer can be detected by an HPLC/MS assay due
to changes in its biochemical properties: 1) increased hydrophobicity and 2)
increased molecular weight. If ULD mutations abrogated exospecificity, equal
proportions of Ubwt and UbG76V W77 would be cleaved from either end of the
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Interestingly, Rpn13 appears to slow processing of triUb for both the wild-type
and E284A UCH37 (Fig 4.6). In the presence of Rpn13, almost no monoubiquitin
is generated by the two hour timepoint but the monoubiquitin band at the two
hour timepoint for UCH37 alone is about eight times more intense. Additionally,
after two hours, UCH37 + Rpn13 still has a significant amount of triubiquitin to
cleave, whereas UCH37 alone has cleaved almost all of its triubiquitin down to
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4.4 Discussion
We have analyzed the contribution of UCH37’s ULD and found it to
provide 1) exo-specificity through binding to ubiquitin’s Lys48 and 2) a means of
activation of the enzyme through interactions with Rpn13. After analysis of
ubiquitin-AMC cleavage by ULD mutants in the presence and absence of Rpn13,
we have identified Glu284 as a critical regulator of Rpn13’s activation, in that
when it is mutated to Ala, activation is lost.
We have generated a novel polyubiquitin for the study of directionalspecific cleavage, triUbG76V W77, which allows detection of a monoubiquitin variant
by differences in molecular weight, hydrophobicity, and molar absorptivity. We
have not utilized this triubiquitin for exo-specificity assays yet, but have analyzed
UCH37’s ability to process tetra-, tri-, and di-ubiquitin in the presence and
absence of Rpn13. It initially appears that Rpn13 slows polyubiquitin cleavage by
UCH37, which has been noted by others but not fully explored9. The investigation
into the mechanism of activation of UCH37 has yet to be completely exhausted,
especially as it pertains to polyubiquitin cleavage. However, our novel substrate
has broader uses for other directional-specific deubiquitinating enzymes that
have sufficient rates of polyubiquitin cleavage and may be a useful tool within this
field.
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CHAPTER 5: RECENT FINDINGS ON THE STRUCTURE AND ACTIVATION
OF UCH37 AND OTHER DEUBIQUITINASES

5.1 Introduction
As of the writing of this document, recent work by two groups has
uncovered two novel structures of UCH37: (1) bound to its activator, Rpn13, and
ubiquitin and (2) bound to a fragment of NFRKB, its deactivator and a component
of the Ino80 complex, both done by Vanderlinden et. al, 2015 and Sahtoe et. al,
2015 1,2. These papers confirm some of the findings of this work, as well as leave
some questions open still open about how UCH37 is regulated. This chapter will
encompass an analysis of the new structures of UCH37 followed by a review of
deubiquitinating enzymes whose specificity and activation rely on small structural
elements, such as loops, in the same manner as UCH37.

5.2 Analysis of UCH37-Rpn13-Ub and UCH37-NFRKB-Ub Structures
Both structures reveal dramatic conformational changes on the part of
UCH37’s ULD domain (Fig 5.1) The ULD of apo UCH37 involves a helix-turnhelix (α9 and α10) followed by a shorter helix, α11, and ending with a short
unstructured loop, as the structure lacks density for the final 18 amino acids of
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stabilization of an open conformation of the crossover loop likely allows improved
substrate binding and catalysis, especially for the proximal ubiquitin monomer not
seen in these structures. Mutations to Met148 and Phe149 render the enzyme
unable to be activated by Rpn13 in UbAMC assays1,2. It can be predicted that the
rest of the crossover loop would be visualized in a UCH37-diubiquitin-Rpn13
structure, and that more of the residues in this region would contribute to
substrate stabilization at the active site, especially the isopeptide bond.
Alternatively, it is possible that the cross over loop maintains its dynamic
character throughout catalytic steps of the enzyme, independent of substrate
binding.

5.2.2 NFRKB Mode of Inhibition
The structures of UCH37 bound to the Ino80 component, NFRKB,
illuminate the way in which the DUB is inhibited catalytically through both its
active and distal sites. NFRKB hijacks the distal region of UCH37 that binds to
the Leu8-Thr9 hairpin of ubiquitin, a key motif within ubiquitin for binding. NFRKB
buries its own Phe100 and Arg101 within the distal pocket, occluding ubiquitin
binding (Fig 5.3). Additionally, the large helix of NFRKB that lies across the active
site face of UCH37 induces small conformational strains that lead to an
unproductive orientation of the active site. The catalytic His has rotated and now
lies an unproductive 6.3 Å from the catalytic cysteine. All of these small changes
can be utilized for small-molecule targeting of UCH37, as they directly occupy
binding sites of ubiquitin.

86

Figure
F
5.3: Mode
M
of NF
FRKB inhib
bition of UC
CH37. NFRK
KB inhibitio
on of UCH3
37 by
B)
B active siite rearrang
gement an
nd C) occlu
usion of th
he UCH37 distal ubiq
quitin
binding site. NFRKB is shown in
n yellow (P
PDB ID 4W
WLP), ubiquitin in ora
ange,
UCH37
U
apo in purple (PDB
(
ID 3IH
HR), UCH3
37 bound to
o NFRKB a
and Ub in g
green
(P
PDB ID 4W
WLP), and UCH37 bound
b
to R
Rpn13 and
d Ub (4WL
LR). Rpn13
3 not
shown.

87
5.3 Analysis of Kinetic Findings in Vanderlinden et. al and Sahtoe et. al
Interestingly, these groups studied the activation of the enzyme in UbAMC
hydrolysis assays using one of the ULD mutants discussed earlier, E284A in my
studies, but numbered E283A in the isoform these groups used. They found that
Rpn13 lowers the KM of UCH37 for ubiquitin 5-fold, but that the KM of the E283A
mutant in the presence of Rpn13 is only 1.5-fold improved compared to UCH37
alone, indicating that this residue may be essential to its activation mechanism,
similar to the results presented previously (Section 4.3.2)2. These results validate
our earlier findings, that E284 is essential to the activation mechanism of UCH37.

5.4 Small Structures Effect Large Changes: A Review of Deubiquitinases
Among the ~100 deubiquitinating enzymes in the human genome, a little
less than half of these do not contain auxiliary ubiquitin binding domains or
ubiquitin-like domains beyond their active sites3. These deubiquitinases must rely
on conformational movement and binding pockets inherent in their active sites
alone, or utilize non-canonical interactions with ubiquitin to bind substrate. There
have been many thorough reviews of the various ubiquitin binding and ubiquitin
like domains; however, little focus has been drawn to the smaller dynamic
movements that significantly contribute to deubiquitinating enzyme catalysis4-8.
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5.4.1 Unproductive Active Sites
One of the simplest, but integral, conformational changes within
deubiquitinases (DUBs) is the reorientation of catalytic residues from an
unproductive form in the apo enzyme to a productive conformation upon ubiquitin
binding. This has been seen in structures of the cysteine protease DUBs and
frequently involves misaligned catalytic cysteines or histidines within their papainlike active sites, less often their catalytic aspartic acid or stabilizing oxyanion
glutamine residues (Fig 5.4).
Catalytic rearrangement occurs upon ubiquitin binding for the UCH family
members UCHL19,10 and UCH371,2,11-14. In the apo UCHL1 active site, the
catalytic histidine resides 8.2 Å away from the catalytic cysteine and is turned 90°
from the typical orientation of a papain-like active site, an unproductive distance
for catalysis9. Upon ubiquitin binding, the histidine swings 90° to lay in-plane with
the catalytic Cys and has moved to a productive 4 Å distance10. In the apo active
site of UCH37, the catalytic His is in a productive orientation, but its catalytic
cysteine is rotated inwards, toward the His residue rather than towards the rest of
the catalytic cleft where ubiquitin will bind11-13. Upon ubiquitin binding, the Cys
rotates 70° to face Gly76 of ubiquitin, an appropriate conformation1,2,14.
Unproductive active sites have been found in the active sites of OTUdomain containing DUBs as well, both OTU1B, K48-specific, and OTULIN, a
linear polyubiquitin-cleaving DUB. Upon binding to ubiquitin, OTUB1 has a
similar conformational change to UCHL1 and UCH37; its His rotates down 90° to
lock in plane with the catalytic Cys, and its Cys flips inward to face Gly76 of
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ubiquitin, altogether moving the two residues closer by 3 Å into a catalyticallyproductive conformation15,16 (Fig 5.4). The structure of OTULIN’s active site has
partial occupancy for two distinct orientations: one in which the catalytic His and
Cys are in appropriate conformations, and one in which the catalytic His is flipped
to occupy the space which Gly76 resides in the linear diubiquitin-bound
structure17.
HAUSP/USP7, one of the most well-characterized USP-family DUBs also
contains a misaligned active site, wherein its catalytic Cys is positioned 10 Å
away from the catalytic His (Fig 5.4). Upon ubiquitin binding, its catalytic Cys,
His, and Asp move closer together, to a 3.7 Å distance between the Cys and His
and a 2.7 Å distance between the His and Asp.
The current theory as to why these DUBs prefer a catalyticallyunproductive active site orientation in absence of ubiquitin is that it may protect
against oxidation18. Some deubiquitinases have been found to be highly
susceptible to oxidation, which can lead to irreversible modification (sulphinic or
sulphonic acid) of their catalytic cysteines, rendering the enzyme catalytically
dead. In the seminal work describing DUB oxidation, the OTU A20 was capable
of an initial state of reversible oxidation, which would attain irreversibility upon
continued exposure to the oxidant18. A20 does not have a misaligned active site,
however it is believed that DUBs with misoriented cysteines may induce
protective interactions with nearby residues, keeping the cysteine shielded from
oxidants.
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5.4.2 Insertions and the JAMM Domain
Regulation of JAMM domain containing deubiquitinating enzymes is
mainly held by their insertion domains, numbered Ins-1 and Ins-219. The
insertions act as substrate stabilizers and confer specificity, as seen in the
structure of AMSH-LP bound to diubiquitin19 (Fig 5.5). AMSH-LP uses the sheets
of Ins-1 to bind the distal ubiquitin monomer and stabilize the isopeptide bond for
cleavage, and Ins-2 for additional isopeptide stabilization and binding of the
proximal ubiquitin monomer. Superposition of the structures of human AMSH,
another JAMM family DUB, and the AMSH-like S. pombe orthologue Sst2 on the
AMSH-LP structure shows similar modes of binding and stabilization by their
highly-conserved insertion domains. These small domains provide significant
contribution to catalysis; when mutated, they can render the enzyme catalytically
impaired. However, mutations to Ins-2 do not contribute to substrate binding as
they only affect kcat, not KM20,21. The isopeptide contacts by the insertions also
maintain specificity, in that AMSH-LP, AMSH, and Sst2 are all highly specific for
K63-linked polyubiquitin chains.
In contrast, two structures were recently solved for Rpn11, the JAMM DUB
resident in the 26S proteasome responsible for en bloc cleavage of ubiquitin
chains from proteasomal substrates, in which only Ins-1 was utilized for substrate
recognition and catalysis22-24. Ins-2 does not contribute to substrate catalysis;
rather, it assists docking Rpn11 to the proteasomal subunit Rpn2, as predicted
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displays an ordered crossover loop that contributes some interactions to
ubiquitin’s C-terminal tail, buried within the active site (Fig 5.6). Only UCH37 still
lacks an ordered crossover loop, even in the presence of ubiquitin and its
activator, the proteasomal subunit Rpn131,2.
Through diubiquitin cleavage assays and protein chimeras altering the
length of the crossover loop, it is apparent that this loop is responsible for
substrate specificity by steric filtering32,33. Generally, the UCH family is believed
to only cleave small moieties from the C-terminus of ubiquitin, not processing of
polyubiquitin. The smaller family members, human UCHL1, human UCHL3, and
yeast YUH1, which contain solely a UCH domain, have the shortest crossover
loops and are not capable of polyubiquitin cleavage, only cleavage of ubiquitinAMC, a fluorogenic ubiquitin substrate with only the small AMC fluorescent group
attached to its C-terminus. The two larger UCH family members, UCH37 and
BAP1, have C-terminal extensions beyond their catalytic domains and contain
longer crossover loops than the other family members, which is believed to allow
them to cleave polyubiquitin. A Drosophila homolog of BAP1, Calypso, has been
shown to deubiquitinate histone H2B34 and UCH37 is proteasome-bound, and
therefore must process the variety of polyubiquitinated prey captured by the 26S.
The substrate-filtering theory was proven by an elegant experiment in which the
crossover loop of UCH37 was expanded by a poly-glycine insertion32. This
chimeric DUB was capable of both K48- and K63-polyubiquitin chain cleavage32.
Within that same study, the crossover loop of wild-type UCHL3 was
biochemically nicked, but this damage did not inhibit the DUB’s cleavage of
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known case of this is seen in the structures of USP14 alone and bound to
ubiquitin-aldehyde35. In its apo form, USP14’s active site is blocked by two loops,
BL1 and BL2, which occupy a portion of the space where ubiquitin’s C-terminal
tail would bind in order to access its catalytic cysteine (Fig 5.7). Upon binding to
ubiquitin, the entirety of these loops, as well as individual side chains, open up to
allow ubiquitin binding. Oddly, many of the residues within these loops are also
responsible for ubiquitin binding, such as Tyr333 and Phe331. These loops are
attributed to USP14’s poor reactivity with ubiquitin probes, namely ubiquitin-vinyl
sulfone, but that it becomes activated upon association with the 26S proteasome,
potentially through conformational restrains of these loops into a more open
form35. Although many other USP family DUBs contain loops within this region,
such as HAUSP/USP7, they do not sterically block those USPs active sites. It is
believed that the length and conformation of these loops confer USP14 with
unique reactivity compared to other USP family DUBs.

5.5 Conclusions
Through examination of the recent UCH37 activating and deactivating xray crystal structures as well as an assessment of other small conformational
contributions to the regulation of deubiquitinating enzymes, we have a newfound
appreciation for the layers of specificity and mechanisms of action of DUBs, a
class of enzymes which process an incredible variety of cellular substrates. Only
~100 DUBs specifically recognize monoubiquitinated substrates, 8 homotypic
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chain types, and a startling number of mixed linkage chain possibilities. Even
more shocking is that only half of them require additional ubiquitin binding
domains beyond their catalytic core in order to attain specificity and improve
substrate binding. DUBs containing only a catalytic domain rely on small
structures within themselves to restrict absolute specificity, as in the case of the
JAMM DUBs AMSH and AMSH-LP, or to allow processing of a broad spectrum
of substrates at a highly specific location and under certain conditions, as in the
case of the proteasomal DUBs Rpn11, USP14, and UCH37.
Although we have uncovered significant information regarding the binding
and catalysis of ubiquitin, as well as the binding and activation of Rpn13, to
UCH37, many questions still remain regarding its ability to process polyubiquitin
at the 26S proteasome. Despite our structural findings regarding its exo-specific
recognition of Lys48-linked chains, it is highly implausible that UCH37 would
have such limited polyubiquitin processing skills at the proteasome, with
increasing reports of proteasome processing of non-canonical ubiquitin
signals36,37. Further structural and biochemical studies of UCH37 within the
context of the 26S proteasome are needed to understand its role in the coupling
of deubiquitination and degradation.
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APPENDIX

Inhibition of Uch37 and Usp14 at the 26s Proteasome and Its Effects on
Degradation
6.1 Introduction
Although UCH37 is capable of activation by Rpn13 alone, its
activity is further enhanced within the context of the entire 26S proteasome, a
mechanism of activation which remains a mystery1-3. Due to UCH37’s poor
cleavage of di- or polyubiquitin substrates alone and in the presence of Rpn13, it
became clear that activity assays would not succeed without the entire 26S
proteasome present as an activator. To this end, we pursued purification of
endogenous 26S from rabbit tissue using an affinity-tag method developed by the
Goldberg group4,5. Using this proteasome, we hoped to study the roles of the
deubiquitinases UCH37 and USP14 within overall protein degradation and
whether their activities are coupled to the rate of degradation of polyubiquitinated
substrates.
This purification method relies on the affinity of the Rpn1 and Rpn10
subunits of the 26S proteasome for the Ubl domain of Rad23B, a shuttle factor

103

Figure
F
A 6.1: Sche
eme of Ubl-UIM pu
urification method o
of endogenous
proteasomes.

capable of binding
b
to either
e
of those subun its6,7. Its Ubl binds to either the Ublbinding dom
main of Rpn1 or to one of the UIM doma
ains of Rpn
n10, a ubiq
quitin
eceptor. Fo
or purification of the proteasome
e, the Ubl of Rad23B
B is fused to a
re
GST-tag,
G
allowing
a
im
mmobilizatio
on on glu
utathione b
beads. Pro
oteasomes are
captured by
y this GST--Ubl, non-s
specifically binding prroteins are washed a
away,
e proteasom
me is elute
ed by addition of a 6xH
His-tagged UIM of Rp
pn10,
and then the
which
w
binds
s to the GS
ST-Ubl and
d releases the proteasome. Exccess His-UIIM is
re
emoved by a subtraction step ov
ver Ni NTA beads. Th
his method is considerred a
more
m
gentle
e purification method than
t
the tra
aditional su
ucrose or glycerol gradient

104
centrifugation method or the TAP- or FLAG-tagged Rpn11 method, allowing
association of transient factors and ensuring the presence of the associated
deubiquitinases, UCH37 and USP144,5. This purification method is outlined in
Figure 6.1.
The goal of this purification method is to investigate the contribution of
UCH37 and USP14 to proteasomal degradation. There is evidence for the role of
USP14 from purified S. cerevisiae proteasomes, however, these lack UCH378,9.
The goal of the following work is to understand how inhibition of UCH37 and
USP14, achieved by incubation with the suicide inhibitor UbVME, affects
substrate degradation and deubiquitination.

6.2 Methods

6.2.1 Purification of Rabbit 26S Proteasomes
Following the method established by Besche et. al, we purified
endogenous levels of 26S proteasome from rabbit tissue (Pel-freez)4,5. This
affinity-tag method relied on the affinity of the proteasomal shuttle factor,
Rad23B, specifically its Ubl domain, for either Rpn10’s UIM domain or Rpn1’s
Ubl-binding site6,7. 2-4 grams of rabbit muscle tissue were homogenized on ice in
proteasome purification buffer (25 mM HEPES pH 7.5, 50 mM NaCl, 5 mM
MgCl2, 10% glycerol), PB, to which 1 mM ATP and 1 mM DTT were added, and
then were spun down at 100,000xg for 1 hour. 2 mg of GST-tagged Rad23B Ubl,
which had been previously purified recombinantly from E. coli, was immobilized
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on glutathione beads and any excess washed off with PB. Rabbit lysate was
rocked with immobilized GST-Ubl for 2 hours at 4°C. Beads were collected in an
empty glass column and unbound proteins were allowed to flow through. 20
column volumes of PB with added ATP and DTT were used to wash the beads. 2
mg of 6xHis-tagged Rpn10 UIM was added to the beads and was rocked
overnight at 4°C to induce elution of pure proteasomes. Proteasomes were then
run over Ni NTA beads to re-capture the His-UIM. Pure proteasomes were
concentrated down and flash frozen as aliquots.

6.2.2 20S Activity Assays
To confirm the presence of the 20S core particle and test its activity, the
hydrolysis of succinate-Leu-Leu-Val-Tyr-AMC, a known 20S substrate, was
measured in the presence of rabbit 26S proteasomes. Suc-LLVY-AMC was
dissolved in DMSO. 5 nM 26S proteasome was diluted in AMC assay buffer
containing 50 mM Tris pH 7.6, 0.5 mM EDTA, 0.1% bovine serum albumin, and 5
mM DTT and allowed to reach 30°C. 100 µM Suc-LLVY-AMC was added to 5 nM
proteasome in assay buffer and AMC hydrolysis was measured on a Tecan plate
reader at 380 nm excitation wavelength and 465 nm emission wavelength at
30°C for 1 hr. Progress curves were plotted in Kaleidagraph.
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6.2.3 Ubiquitin-AMC Hydrolysis Assays
To test the deubiquitinating activity of endogenous UCH37 and USP14,
hydrolysis of UbAMC was measured. Proteasomes were diluted to 5 nM in
reaction buffer, 50 mM Tris pH 7.6, 0.5 mM EDTA, 0.1% bovine serum albumin,
and 5 mM DTT. Reactions were initiated by addition of UbAMC (Boston
Biochem) and were measured on a Tecan fluorescence plate reader (Männedorf,
Switzerland) with 380 nm excitation wavelength and 465 nm emission
wavelength at 30°C for 1 hr. Progress curves were plotted in Kaleidagraph.

6.2.4 Synthesis and Degradation of GFP-Titin-CyclinPY Substrate
In order to measure rates of degradation by the rabbit 26S, a
polyubiquitinated proteasomal substrate was needed. In the literature, there are a
handful of substrates, however, each is limited in scope and/or synthetic
simplicity. We utilized a substrate developed by the Martin group at UC Berkeley,
a GFP-tagged unstructured protein, titin, fused to cyclin, a known proteasomal
substrate, with an engineered PY motif, a degron which signals E3 ligases for
polyubiquitination10,11. After expression and purification from E. coli, the GFPtitin-cyclinPY was polyubiquitinated by the E3 ligase Rsp5, also bacterially
expressed.
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mM ATP, 1 mM DTT, and an ATP recycling system (creatine phosphokinase,
inorganic pyrophosphate, creatine phosphate) in 50 mM HEPES pH 7.5, 50 mM
NaCl, 10% glycerol. The reactions were run at 25 °C and were quenched with 5x
SDS PAGE buffer.
6.3 Results

6.3.1 Impact of Deubiquitinase Inhibition on Proteasome Degradation
The 26S proteasome was purified from rabbit muscle tissue using the UblUIM method developed by the Goldberg group and can be seen in Fig 6.34,5.
This method did not purify a large amount of proteasomes and retained the GSTUbl and His-UIM proteins despite subtraction over Ni-NTA beads. However, there
was sufficient to study the effects of inhibition of the associated deubiquitinases,
UCH37 and USP14, by UbVME treatment. To this end, proteasomes were
treated with and without 1 µM UbVME for 2 hours on ice to catalytically inactivate
the endogenous associated deubiquitinases. Then each sample was assessed
for its deubiquitinating activity by UbAMC hydrolysis assays and for its 20S core
particle activity using a fluorogenic peptide substrate, succinate-Leu-Leu-Val-TyrAMC, or SucLLVY-AMC. Not surprisingly, in the presence or absence of UbVME,
the proteasome’s 20S activity was not changed (Fig 6.4). However,
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degradation compared to uninhibited proteasomes, despite activity of the 20S
core particle being unchanged in the presence of UbVME (Fig 6.4). This would
suggest that deubiquitination by UCH37 and USP14 are coupled to degradation,
a theory still under investigation.
Due to this result, we were curious about the effect of simultaneous
deubiquitinase and 20S inhibition, achieved by the addition of UbVME and the
20S inhibitor MG132. MG132 inhibits the β5 subunit of the 20S core particle,
thereby slowing its proteolytic activities by inhibiting one of the proteolytic
subunits12,13. We were curious as to the contribution of UbVME in slowing
proteasomal degradation compared to MG132, a well-characterized inhibitor.
Incubation of the 26S with inhibitors was done on ice for 2 hours in the presence
of either MG132 or a DMSO control, or UbVME or a buffer control. First, we
tested 20S and deubiquitinase activity by SucLLVY-AMC and UbAMC hydrolysis
(Fig 6.5). As expected, MG132 inhibits 20S activity but not deubiquitinating
activity, and UbVME inhibits deubiquitinating activity but not 20S activity. 20S
activity was slightly enhanced in the presence of UbVME, a phenomenon
previously observed by the Goldberg group (using ubiquitin-aldehyde), but
explained as an increase in AAA ATPase activity upstream14. Interestingly,
MG132 seems to slightly enhance deubiquitinating activity, but is within error,
therefore was not further investigated. These results indicate appropriate levels
of inhibition of the 20S and deubiquitinases by their respective inhibitors, so
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these samples were used to test degradation of the GFP-titin-cyclinPY-Ubn
substrate (Fig 6.5).
The rates of degradation of the GFP-Ubn substrate were measured by
running time points on SDS PAGE gels to show disappearance of the heavily
polyubiquitinated band, which were subsequently quantified by ImageJ analysis.
MG132 alone appears to only decrease degradation by about 25% compared to
the uninhibited sample, which is understandable because it only inhibits one of
the catalytic subunits of the 20S, rather than all three. UbVME alone shows a
decrease of 50% in degradation, similar to the results shown above in Figure 6.5.
However, the combination of MG132 and UbAMC slows degradation by >90%
compared to the uninhibited sample. As this amount is even greater than the
additive 75% of the two inhibitors alone, this result indicates that significant
inhibition of degradation is occurring in a coupled deubiquitination-degradation
mechanism.
6.4 Further Directions
Investigation into the coupling of UCH37/USP14 deubiquitination and
degradation by the 26S proteasome could prove vital to our understanding of all
protein degradation, but especially how these deubiquitinases may be the first
step in regulation of this cellular machine. The experiments addressed here
indicate that deubiquitination may be coupled to degradation, however, it is
necessary to separate out the effects of deubiquitination by Rpn11 before any
conclusions can be made. This could be achieved by incubation of proteasomes
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with 1,10-phenanthroline, a known inhibitor of Rpn1112,15-17. It is necessary to
determine if deubiquitination by the cysteine protease deubiquitinases has a
separate function from that of Rpn11 and which level of deubiquitination
contributes most to slowing the rate of proteasomal degradation.
Additionally, the assays described here rely on SDS PAGE gel analysis of
the disappearance of a band of highly polyubiquitinated GFP substrates,
however, disappearance does not isolate deubiquitination from degradation.
These experiments are currently being pursued by a labmate, Michael Sheedlo,
using a T7 probe and polyubiquitinated Sic1, another proteasome substrate, to
determine the contributions of deubiquitination vs degradation. More specific
answers to these questions are needed before we can definitively say that
deubiquitination by UCH37 and USP14 are indeed coupled to and a contributing
factor during proteasomal degradation.
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ABSTRACT: Ubiquitination is countered by a group of
enzymes collectively called deubiquitinases (DUBs); ∼100 of
them can be found in the human genome. One of the most
interesting aspects of these enzymes is the ability of some
members to selectively recognize speciﬁc linkage types
between ubiquitin in polyubiquitin chains and their endo
and exo speciﬁcity. The structural basis of exo-speciﬁc
deubiquitination catalyzed by a DUB is poorly understood.
UCH37, a cysteine DUB conserved from fungi to humans, is a
proteasome-associated factor that regulates the proteasome by
sequentially cleaving polyubiquitin chains from their distal ends, i.e., by exo-speciﬁc deubiquitination. In addition to the catalytic
domain, the DUB features a functionally uncharacterized UCH37-like domain (ULD), presumed to keep the enzyme in an
inhibited state in its proteasome-free form. Herein we report the crystal structure of two constructs of UCH37 from Trichinella
spiralis in complex with a ubiquitin-based suicide inhibitor, ubiquitin vinyl methyl ester (UbVME). These structures show that
the ULD makes direct contact with ubiquitin stabilizing a highly unusual intramolecular salt bridge between Lys48 and Glu51 of
ubiquitin, an interaction that would be favored only with the distal ubiquitin but not with the internal ones in a Lys48-linked
polyubiquitin chain. An inspection of 39 DUB−ubiquitin structures in the Protein Data Bank reveals the uniqueness of the salt
bridge in ubiquitin bound to UCH37, an interaction that disappears when the ULD is deleted, as revealed in the structure of the
catalytic domain alone bound to UbVME. The structural data are consistent with previously reported mutational data on the
mammalian enzyme, which, together with the fact that the ULD residues that bind to ubiquitin are conserved, points to a similar
mechanism behind the exo speciﬁcity of the human enzyme. To the best of our knowledge, these data provide the only structural
example so far of how the exo speciﬁcity of a DUB can be determined by its noncatalytic domain. Thus, our data show that,
contrary to its proposed inhibitory role, the ULD actually contributes to substrate recognition and could be a major determinant
of the proteasome-associated function of UCH37. Moreover, our structures show that the unproductively oriented catalytic
cysteine in the free enzyme is aligned correctly when ubiquitin binds, suggesting a mechanism for ubiquitin selectivity.

T

Entry of substrates into the CP is regulated by the RP, primarily
by opening and closing of the substrate translocation channel.
Before the substrate is translocated into the narrow channel
leading to the lumen of the CP, it is obligatorily deubiquitinated
with the help of the RP-resident JAMM metalloprotease
Rpn1114−16 and unfolded by Rpt subunits that sit within the
base subcomplex of the RP.7,9,14 However, additional regulation

he ubiquitin proteasome system (UPS), present in all
eukaryotes, is responsible for the majority of controlled
degradation and recycling of proteins within the cell.1−5
Polyubiquitinated, and to some extent monoubiquitinated,
proteins are recognized and degraded by the 26S proteasome, a
2.5 MDa self-compartmentalizing proteolytic complex.6−13 It is
composed of two major units: the 20S core particle (CP)
consisting of 28 subunits and the 19S regulatory particle (RP)
containing 19 subunits in yeast. The proteolytic active sites are
housed within the luminal chamber of the barrel-shaped CP,
capped on both ends by the RP, which contains ubiquitin
receptors and enzymes that prepare substrates for degradation.
© 2013 American Chemical Society
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thought to behave as an “editor”, relieving poorly ubiquitinated
substrates from degradation by sequentially dismantling their
K48-linked polyubiquitin chains from the very distal end,
removing one ubiquitin at a time.37,38,45 Such a type of chain
disassembling activity can be termed as an exo cleavage activity
in contrast to the endo activity, which leads to dismantling of
chains by cleavage between internal ubiquitins. Although it has
respectable UbAMC (ubiquitin aminomethylcoumarin) hydrolysis activity in its unbound form, UCH37 has been shown to
require association with the proteasome to cleave diubiquitin
(and polyubiquitin) chains.37 Additionally, its UbAMC
hydrolysis activity is enhanced upon binding with Rpn13.37,54
Interestingly, UCH37 also associates in the nucleus with the
human Ino80 chromatin remodeling complex, where it is held
in an inactive state compared to the free enzyme.55 It thus
serves as an example of a DUB whose catalytic activity is both
positively and negatively regulated by binding to speciﬁc
protein partners, making it an attractive target for structural
studies. Crystal structures have been determined for both the
catalytic domain and full-length human UCH37;56−58 however,
the mechanism of its catalytic regulation upon binding to
associated protein factors is not known. Any mechanistic
understanding of its regulation must require structural
information about UCH37 and its catalytic domain bound to
ubiquitin, which has yet to be reported.
TsUCH37 is a recently characterized lower-organism
homologue of UCH37 from Trichinella spiralis (Ts), an
infectious helminth found nearly worldwide. TsUCH37 was
identiﬁed by White et al. by incubation of the whole-cell lysate
of Ts larvae with the HA-UbVME probe (HA, the
hemagglutinin epitope, fused with the N-terminus of ubiquitin
vinyl methyl ester), an epitope-tagged irreversible inhibitor of
cysteine DUBs.59 Its structural and functional homology with
human UCH37 was then conﬁrmed by sequence analysis, coimmunoprecipitation with proteasomal subunits, and UbAMC
hydrolysis assays. TsUCH37 is 45% identical to its human
homologue and was shown to pull down TsADRM1, the
corresponding Rpn13 homologue, by co-immunoprecipitation.59 The sequence and functional conservation between
the Ts and human enzymes implies a similar chain-editing role
of the former at the proteasome. To understand the
mechanisms associated with UCH37, we have crystallized two
constructs of TsUCH37 bound to ubiquitin vinyl methyl ester.
The structures illuminate the mode of ubiquitin recognition in
the enzyme by revealing binding interactions with the catalytic
domain, which are conserved among UCH enzymes, and
interactions unique to UCH37, notably ubiquitin binding by
the ULD, providing further explanation of the proteasomeassociated exo-speciﬁc deubiquitination activity of the DUB.

is performed by proteasome-associated deubiquitinating
enzymes, whose underlying mechanism is still poorly understood.7,17
Attachment of ubiquitin to a lysine residue(s) on target
proteins is catalyzed by the sequential action of three enzymatic
systems: E1 (ubiquitin-activating), E2 (ubiquitin-conjugating),
and E3 (ubiquitin-ligating) enzymes.18,19 Usually, ubiquitination of a target protein results in the attachment of a
polyubiquitin chain in which successive ubiquitin moieties are
attached to one of the seven lysines, or the N-terminal amino
group of the preceding monomer, to generate a homopolymeric
structure.18,20 Polyubiquitin chains of a distinct topology are
thus generated depending on which amino group of ubiquitin is
used for chain extension (lysines 6, 11, 27, 29, 33, 48, and 63 or
the amino group of Met1). A polyubiquitin chain of a speciﬁc
topology is meant for a speciﬁc type of functional outcome.20−25 For example, a Lys48 (K48)-linked chain usually
serves as the signal for proteasomal degradation, whereas K63
chains signal other types of functions such as endocytosis, DNA
repair, and NF-κB signaling.24,26
Ubiquitination works as a reversible post-translational
modiﬁcation, like phosphorylation. Deubiquitinating enzymes,
or DUBs, can hydrolytically remove ubiquitin from protein
adducts, thereby opposing the action of ubiquitin conjugating
machinery.27−33 Consequently, DUBs have been found to play
important regulatory roles in numerous ubiquitin-dependent
cellular processes.32−35 In mechanistic terms, these enzymes
can be categorized into two main groups: cysteine proteases
and zinc metalloproteases. The zinc metalloproteases consist of
only one family, the JAB1/MPN/MOV34 metalloenzymes
(JAMMs). The cysteine proteases are further broken down into
four families based on the structure of their catalytic domain:
ubiquitin carboxyl-terminal hydrolases (UCHs), ubiquitinspeciﬁc proteases (USPs), ovarian tumor proteases (OTUs),
and Machado-Josephin domain proteases (MJDs).32
UCH37 (also known as UCHL5) is a 37 kDa DUB of the
UCH family and is one of the two proteasome-associated
DUBs, the other being USP14 (Ubp6 in yeast), known to
regulate protein degradation by the mammalian proteasome.36−40 These associated DUBs, along with Rpn11, a
constitutive member of the RP, conduct deubiquitination at the
proteasome. However, the activities of the three enzymes are
distinct. Rpn11 is responsible for en-bloc removal of
polyubiquitin chains prior to (or concurrent with) unfolding
and translocation of the substrate into the CP, an activity that
appears to be coupled to substrate degradation.15−17 USP14
and UCH37 on the other hand are known to have chaintrimming functions.17,37,41 The importance of these associated
DUBs to proteasome function was revealed through
pharmacological inhibition of these enzymes. A small-molecule
inhibitor of USP14 appears to accelerate proteasomal
degradation of certain substrates, whereas UCH37 inhibition
can stall proteolysis, consistent with distinct functional roles
played by the two enzymes.42−44
UCH37 was ﬁrst identiﬁed as the PA700 isopeptidase, the
cysteine DUB tightly associated with the RP, also known as
PA700.38,45,46 Like other UCH family members, it contains a
conserved catalytic triad of a cysteine, a histidine, and an
aspartate. UCH37 has a canonical UCH domain that is 45%
similar to UCHL1 and 49% similar to UCHL3, its singledomain family members.47−50 It also has an additional Cterminal tail domain responsible for its interaction with the
Rpn13 subunit of the RP.51−54 Proteasome-bound UCH37 is

■

MATERIALS AND METHODS

Cloning, Expression, and Puriﬁcation. TsUCH37cat.
TsUCH37cat (residues 1−226) was subcloned from the fulllength construct (residues 1−309) in pET28a(+) into pGEX6P-1 (GE Biosciences) using BamHI and XhoI restriction sites.
The protein was expressed in Escherichia coli Rosetta cells
(Novagen) grown at 37 °C in LB medium containing 100 μg/L
ampicillin to an OD600 of 1.0 and then induced with 0.5 mM
isopropyl β-D-thiogalactoside (IPTG) at 18 °C for 16 h.
Harvested cells were resuspended in lysis buﬀer (1× phosphate
buﬀered saline and 400 mM KCl) and lysed with a French
press. The lysate was then puriﬁed on a glutathione Stransferase (GST) column (GE Biosciences) followed by
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restraints. The data were run through Phenix Xtriage, which
conﬁrmed the chosen space group, C2, and did not detect
evidence of crystal twinning.63 The completeness of the
crystallographic data for the TsUCH37cat−UbVME complex
was less than ideal (see Table 2); however, this did not hinder
the determination of the structure or the generation of the
structural model presented herein and can be ascribed to poor
completeness in the highest-resolution shells.
TsUCH37ΔC46−UbVME Complex. The TsUCH37ΔC46−
UbVME complex was concentrated to 5 mg/mL in 50 mM
HEPES (pH 7.6) and 2 mM DTT. Crystals were grown in 60
days at room temperature in 0.2 M ammonium chloride (pH
5.8) and 18% PEG3350. Crystals were cryoprotected in
ethylene glycol and ﬂash-frozen in liquid nitrogen. Diﬀraction
data were collected on a Mar300 CCD detector (Mar USA) at
the 23-ID-B beamline at Argonne National Laboratory. Data up
to 2.0 Å were collected on TsUCH37ΔC46−UbVME crystals at
1.033 Å. Data were processed with HKL2000.62
The initial model was obtained by molecular replacement
using the Phenix AutoMR wizard, with a monomer of the
TsUCH37cat−UbVME complex as the search model.63 Manual
model building was conducted in Coot, and structural
reﬁnement was conducted initially in Refmac using TLS
reﬁnement and then using simulated annealing and individual B
factor reﬁnement in Phenix.63,64 The data were run through
Phenix Xtriage, which conﬁrmed the chosen space group, R3,
and did not detect any evidence of crystal twinning.63
UbAMC Hydrolysis Assay. TsUCH37cat was diluted in
reaction buﬀer [50 mM Tris (pH 7.6), 0.5 mM EDTA, 0.1%
bovine serum albumin, and 5 mM DTT] to a ﬁnal reaction
concentration of 7 nM and preincubated at 30 °C for 5 min
prior to the addition of the UbAMC substrate (Boston
Biochem). UbAMC cleavage was measured on a Tecan
(Männedorf, Switzerland) ﬂuorescence plate reader with 380
nm excitation and 465 nm emission wavelengths at 30 °C. Data
were ﬁt to Michaelis−Menten kinetics in SigmaPlot (Systat
Software, San Jose, CA).
Analytical Ultracentrifugation. Sedimentation velocity
experiments were conducted with the Beckman-Coulter XLA
analytical ultracentrifuge. The sample was extensively dialyzed
against 50 mM Tris-HCl, 200 mM NaCl, and 1 mM DTT (pH
7.4). The TsUCH37cat and TsUCH37cat−UbVME complex
concentration ranged from 10 to 32 μM. The samples were
centrifuged at 50000 rpm using a two-sector 1.2 cm path-length
carbon-ﬁlled Epon centerpiece. The experiments were conducted on an An-50 Ti rotor at 20 °C. The density and relative
viscosity of the buﬀers were calculated using SEDNTERP
version 1.09 (http://www.rasmb.bbri.org/rasmb/windows/
sednterp-philo): 1.0079 g/mL and 0.01036 P, respectively.
The partial speciﬁc volume (vbar) of the protein was also
calculated from the protein sequence using SEDNTERP
(0.7340 mL/g for TsUCH37cat and 0.7317 mL/g for the
TsUCH37cat−UbVME complex). The samples were monitored
at 280 nm with a 4 min delay and 150 scans. The c(s)
distributions were analyzed using SEDFIT version 13.0b.65
Molecular Dynamics Simulations. A model of full-length
TsUCH37 was generated by the SwissModel homology
modeling server using the structure of the full-length human
protein as a template.66 Missing ULD residues produced by the
model were appended to the TsUCH37ΔC46 −UbVME
structure in Coot, and a single round of reﬁnement was
conducted in Phenix, to produce a ﬁnal model hereafter termed
“the system”.63,64 The system was solvated in a box of TIP3P

cleavage of the GST tag by PreScission Protease (GE
Biosciences) per the manufacturer’s instructions. It was further
puriﬁed by size exclusion chromatography on a Superdex 75
column (GE Biosciences). Intein-fused ubiquitin1−75 in pTXB1
was expressed in E. coli Rosetta cells and puriﬁed on chitin
beads (New England Biosciences). Ubiquitin vinyl methyl ester
(UbVME) was synthesized by overnight incubation of Ub1−75MESNa (MESNa, sodium mercaptoethanesulfonate) with
glycine vinyl methyl ester and then puriﬁed on a MonoS
cation exchange column (GE Biosciences). Glycine vinyl
methyl ester was synthesized by a modiﬁed, previously
published procedure. 60 TsUCH37 cat was reacted with
UbVME for 4 h, followed by puriﬁcation on a MonoQ anion
exchange column (GE Biosciences) to separate any unreacted
TsUCH37cat. Selenomethionine TsUCH37cat protein (SeMet
TsUCH37cat) was grown in M9 minimal medium supplemented with selenomethionine, reacted with UbVME, and
puriﬁed as described above.
TsUCH37ΔC46. TsUCH37FL was subcloned previously into
pET28a(+) with an N-terminally fused His tag (Novagen).
TsUCH37FL was expressed in E. coli Rosetta cells, grown at 37
°C in LB medium containing 10 μg/L kanamycin to an OD600
of 0.8, and then induced with 0.5 mM IPTG at 18 °C for 16 h.
Harvested cells were resuspended in lysis buﬀer [50 mM TrisHCl (pH 7.6), 200 mM NaCl, and 3 mM β-mercaptoethanol]
and lysed with a French press. His-tagged TsUCH37FL was
puriﬁed by immobilized metal aﬃnity chromatography (IMAC)
and eluted with lysis buﬀer including 500 mM imidazole. Eluted
proteins were further puriﬁed by size exclusion chromatography
(SEC) on a Superdex 75 column (GE Biosciences) in 50 mM
HEPES (pH 7.6) and 3 mM dithiothreitol (DTT). SDS−
PAGE on the fractions indicated a cleavage of the full-length
protein, so the construct described is actually a proteolytic
cleavage product of the full-length protein. The crystal structure
(described below) lacks density for the last 46 amino acids from
the C-terminus; therefore, this construct will hereafter be
described as TsUCH37ΔC46. Fractions containing the target
protein were pooled, concentrated, and reacted with UbVME.
UbVME was synthesized and reacted with puriﬁed
TsUCH37ΔC46 as was done with TsUCH37cat. To separate
unreacted TsUCH37ΔC46, the complex was further puriﬁed by
SEC on a Superdex 75 column (GE Biosciences).
Crystallization and Structure Determination.
TsUCH37cat−UbVME Complex. The TsUCH37cat−UbVME
complex was concentrated to 3 mg/mL in 50 mM Tris (pH
7.6), 200 mM NaCl, and 1 mM DTT. Crystals were grown in 2
days at room temperature by hanging drop vapor diﬀusion in 3
M ammonium sulfate and 0.1 M bicine (pH 9.0) with 2 mM Lglutathione (mixture of oxidized and reduced) additive.
Crystals were cryoprotected in 2.5 M sodium malonate and
ﬂash-frozen in liquid nitrogen.61 Diﬀraction data were collected
on a Mar300 CCD detector (Mar USA) at the 23-ID-B
beamline at Argonne National Laboratory (Argonne, IL). Data
up to 1.7 Å were collected on SeMet TsUCH37cat−UbVME
crystals at the selenium peak (0.979 Å) for SAD (singlewavelength anomalous dispersion) phasing. Data were
processed with HKL2000.62
The initial model was obtained by Se-SAD phasing in the
Phenix AutoSol wizard.63 Its sequence was built in using the
Phenix AutoBuild wizard, as well as manual model building in
Coot.63,64 Structural reﬁnement was conducted in Phenix using
TLS reﬁnement (with the entire asymmetric unit taken as one
TLS group), as well as optimized weighting for stereochemical
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Figure 1. (a) Schematic structures representing inhibition of UCH37 by UbVME (I and II). Deﬁnition of proximal and distal ubiquitin in a
diubiquitin substrate (III). Schematic structure of the acyl-enzyme intermediate formed during deubiquitination catalyzed by a cysteine DUB (IV).
The UbVME adduct (II) mimics the acyl-enzyme intermediate (IV), as shown in yellow. (b) Domain diagrams of TsUCH37 constructs compared to
other UCH family members with UCH domains boxed in gray and additional domains boxed and labeled as shown. (c) Kinetic assay of UbAMC
hydrolysis by TsUCH37cat. (d) Analytical ultracentrifugation proﬁles of TsUCH37cat (left) and the TsUCH37cat−UbVME complex (right),
indicating that both are monomeric in solution.

bound to ubiquitin vinyl methyl ester (UbVME) (the
TsUCH37cat−UbVME complex) and the UbVME complex of
the full-length protein. UbVME is a suicide substrate of cysteine
DUBs, which react with the former via nucleophilic attack of
the catalytic cysteine at the vinyl group of the VME moiety,
resulting in an irreversible modiﬁcation whereby a covalent
bond is formed between the catalytic cysteine and the VME
portion of the inhibitor (Figure 1a).36,48,60 This covalent adduct
is thought to mimic the acyl-enzyme intermediate formed
during deubiquitination reactions catalyzed by the DUB (II and
IV in Figure 1a). If diubiquitin is used as the substrate, the
distal ubiquitin moiety is the acyl component of the acylenzyme intermediate, with the proximal ubiquitin acting as the
leaving group during isopeptide bond hydrolysis (in diubiquitin, a lysine residue of one ubiquitin, called the proximal
ubiquitin, is linked via an isopeptide bond to the C-terminal
carboxylate group of another ubiquitin, called the distal
ubiquitin) (III in Figure 1a).
The TsUCH37cat−UbVME complex crystallized in the C2
space group with two molecules of the complex in the
asymmetric unit. Our attempts to crystallize the full-length
version, however, were met with limited success, the full-length
protein being susceptible to proteolysis as indicated by at least
two closely migrating bands in an SDS−PAGE gel (data not
shown). While attempting to purify the full-length construct,
we managed to retrieve a truncated version of the protein
lacking 46 amino acids from the C-terminal end of the protein
(see Materials and Methods). This truncated protein was

water with the minimal distance between any solute atom and
the boundary of the box set to 10 Å. The system was
neutralized with 15 Na+ ions, which were automatically
positioned by the tleap program. Molecular dynamics (MD)
simulations were performed using Amber 10 with Amber force
ﬁeld ﬀ03.67 Periodic boundary conditions were applied, and the
full electrostatic energy was calculated using the particle mesh
Ewald (PME) method.68 The simulation consisted of three
sequential steps: energy minimization for 5000 steps (2500
steps of steepest-descent followed by 2500 steps of conjugate
gradient minimization), equilibration for 100 ps of solvent with
the protein restraint with a force constant of 5 kcal mol−1 Å−1,
and a ﬁnal MD simulation for 2 ns. All simulations were
conducted at 300 K with a constant volume. A time step of 2 fs
was used, and the SHAKE algorithm was applied to constrain
the bonds involving hydrogen atoms.69

■

RESULTS

TsUCH37, like its mammalian counterpart, contains a catalytic
UCH domain, and an additional polypeptide chain following it
called the C-terminal tail comprising the conserved UCH37like domain (ULD) followed by a putative KEKE motif (Figure
1b).37,51,70,71 The ULD in human UCH37 is thought to have an
inhibitory role, presumably by folding onto the catalytic domain
thereby occluding ubiquitin binding.37 However, how ubiquitin
binds to UCH37 has not been structurally characterized. To
gain insight into how ubiquitin is recognized by TsUCH37, we
aimed to crystallize both the catalytic domain of TsUCH37
3567
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Table 2. Crystallographic and Reﬁnement Statisticsa

puriﬁed by Ni aﬃnity chromatography and reacted with
UbVME, and the complex was puriﬁed using ion-exchange
chromatography. This complex, hereafter termed the
TsUCH37ΔC46−UbVME complex (TsUCH37 missing the last
46 residues), crystallized in the R3 space group with one
complex in the asymmetric unit.
The catalytic activity of TsUCH37cat was measured with a
UbAMC hydrolysis assay (Figure 1c), which yielded
Michaelis−Menten parameters as shown in Table 1. Compared

SeMet TsUCH37cat−
UbVME
Data Collection
space group
cell dimensions
a, b, c (Å)
α, β, γ (deg)
wavelength (Å)
resolution (Å)
Rsym or Rmergeb (%)
I/σI
completeness (%)
redundancy

Table 1. Kinetic Parameters for TsUCH37cat
enzyme
cat

TsUCH37
UCH37N240a
UCHL3a
UCHL1a
a

KM (nM)

kcat (s−1)

kcat/KM (×105 M−1 s−1)

1085
21493
77.1
47.0

0.37
34
19
0.03

3.4
16
2414
7.4

TsUCH37ΔC46−
UbVME

resolution (Å)
no. of unique
reﬂections
Rworkc/Rfreed
no. of atoms
proteine
ligand
water
average B factor
2
(Å )
protein
ligand
water
rmsd
bond lengths
(Å)
bond angles
(deg)
Ramachandran plot
(%)
favored
allowed
outliers

Kinetic parameters previously determined, from ref 75.

to the catalytic domain of human UCH37, TsUCH37cat has an
approximately 20-fold lower KM, indicating a higher aﬃnity for
this substrate compared to that of the human protein, but a
100-fold lower kcat, a substantially lower turnover number.
Consequently, TsUCH37cat is nearly 5-fold less eﬃcient than
the UCH domain of human UCH37.
Crystals of the TsUCH37cat−UbVME complex diﬀracted to
1.7 Å. The structure was determined by single-wavelength
anomalous dispersion (SAD) using anomalous scattering from
selenium (TsUCH37cat was labeled with selenium). Manual
model building using Coot, followed by multiple rounds of
reﬁnement using Phenix, produced a ﬁnal model with an R
factor of 17.4% and an Rfree of 21% (see Table 2 for
crystallographic and reﬁnement parameters).63,64 The ﬁnal
reﬁned model corresponding to the asymmetric unit consists of
two copies of the TsUCH37cat−UbVME complex, composed of
TsUCH37cat, residues 1−226, covalently connected via a
thioether bond linking the catalytic cysteine with the VME
group of UbVME (residues 1−75 of ubiquitin attached to
GlyVME as the 76th residue, which is modeled as methyl 4amino butanoate). The reﬁned model was of high stereochemical quality, with <0.2% of residues in the disallowed
region of the Ramachandran plot and scoring in the upper 98%
according to Molprobity evaluation.72 The structure of the
TsUCH37ΔC46−UbVME complex (2.0 Å resolution) was
determined by molecular replacement using the
TsUCH37cat−UbVME structure as the search model (Table
2). The ﬁnal reﬁned model with good stereochemical quality
(<0.2% of residues in the disallowed region of the
Ramachandran plot and Molprobity score of 63%) has amino
acids 5−263 of the protein and one UbVME linked via a
thioether bond to the catalytic cysteine. The structures of the
UCH domain in the two constructs are very similar, except for
two loop regions (see below), with Cα root-mean-square
deviations (rmsds) of 0.32 Å between the two (the loop regions
were excluded from the calculation of the rmsd). When
discussing the structure of the UCH domain alone or its
interaction with UbVME, we will therefore use the structure of
the TsUCH37cat−UbVME complex because its resolution is
higher while speciﬁcally mentioning any structural feature that
is diﬀerent in the UCH domain of TsUCH37ΔC46−UbVME
complex.
Initial analysis of the structure revealed that the two copies in
the asymmetric unit of TsUCH37cat−UbVME crystals are

C121

R3

171.2, 55.8, 73.9
90, 113.4, 90
0.979
50.00−1.70 (1.73−1.70)
8.7 (50.0)
15.9 (3.0)
88.5 (42.0)
6.8 (3.5)
Reﬁnement
27.9−1.7
62326/3126

147.4, 147.4, 40.5
90, 90, 120
1.033
50−2.0 (2.03−2.00)
8.5 (83.8)
4.9 (4.1)
100.0 (100.0)
5.8 (5.7)

17.4/21.1

19.3/24.0

4650
24
437

2428
8
100

36.2
36.5
44.0

43.4
32.4
44.3

0.013

0.009

1.48

1.07

98.1
1.6
0.4

97.7
1.0
1.3

38.6−2.0
22270/2002

a

Numbers in parentheses refer to data in the highest-resolution shell.
Rmerge = ∑|Ih − ⟨Ih⟩|/∑Ih, where Ih is the observed intensity and ⟨Ih⟩
is the average intensity. cRwork = ∑||Fobs| − k|Fcal||/∑|Fobs|. dRfree is the
same as Robs for a selected subset (5 and 9%) of the reﬂections that
was not included in prior reﬁnement calculations. eOrdered residues:
Pro3−Gly141 and Lys153−Asp224 in chain C and Pro3−Gly141 and
Gln152−Gln225 in chain A of the SeMet TsUCH37cat−UbVME
structure and Gly4−Lys57, Thr72−Gly141, and Glu157−Ala263 of
the TsUCH37ΔC46−UbVME structure.
b

linked by a disulﬁde bond between Cys71 of the two
TsUCH37cat chains (Figure 2a). It is possible that the disulﬁde
bond forms because the protein exists as a dimer in solution,
bringing the cysteines into proximity of each other, or is a result
of crystallographic packing. To determine if this disulﬁde is a
crystallographic artifact or a biologically relevant association, we
determined the oligomerization state of complexed and
uncomplexed (apo) TsUCH37cat by sedimentation velocity
analytical ultracentrifugation (AUC). We found that both the
complex and the apo protein exist as monomers in solution
with sedimentation coeﬃcients (S20,w) of 3.3 and 2.8,
respectively (Figure 1d), indicating that this disulﬁde is likely
a result of crystal packing. TsUCH37 is expected to be
predominantly localized to the cytosol, a reducing environment,
and therefore should not rely on disulﬁde-mediated dimerization for catalytic activity. Moreover, the observation that the
3568
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Figure 2. Crystal structures of TsUCH37 constructs bound to UbVME. (a) Dimeric structure of TsUCH37cat bound to UbVME (orange) in
crystals. Monomers are colored teal (chain A) and gray (chain C). The inset shows the disulﬁde bridge that links the two subunits via Cys71. The
electron density is rendered from the 2Fo − Fc map contoured at 1σ. (b) Monomer of the TsUCH37cat−UbVME structure. (c) Structure of the
TsUCH37ΔC46−UbVME complex, with TsUCH37ΔC46 colored olive and UbVME orange.

TsUCH37ΔC46−UbVME complex is a monomer in the
asymmetric unit and that the segment of residues 57−71,
which is used as a part of the dimer interface in the crystals of
the TsUCH37cat−UbVME complex, is disordered in the
TsUCH37ΔC46−UbVME structure (Figures 2 and 3) supports

overall architecture of TsUCH37cat can be seen as bilobal, with
one of the lobes comprising helices α1−α5 and the other
comprising the β-sheets and helix α6. The active site is located
at the interface of the two lobes, with Cys85 from helix α2 in
one lobe and His161 from β3 in the other forming the catalytic
Cys-His pair. An adjacent loop provides the third member of
the triad, Asp176. Most of the secondary structural elements
seen in TsUCH37cat are conserved in UCHL1 and UCHL3,
with the only noticeable diﬀerence being the conformation of a
segment following β2, residues 57−71. This segment is a helix
in UCHL1 and UCHL3 and is in somewhat of an extended
looplike conformation in human UCH37 (hUCH37) but is
fairly ordered; in the structure of the various constructs of
human UCH37 determined so far, this loop has been found to
be in a similar conformation regardless of crystallographic
packing (Figure S1 of the Supporting Information).56−58,74 In
contrast, this segment appears to be ﬂexible in TsUCH37 and is
visualized only in the TsUCH37cat−UbVME structure, in which
it forms the dimer interface between the two subunits in the
asymmetric unit. In the TsUCH37ΔC46−UbVME complex, a
crystallographic monomer, this loop is disordered (Figure 3).
Although the possibility that its binding can inﬂuence the loop
dynamics cannot be ruled out, it is unlikely that UbVME has
anything to do with the dynamic behavior of the loop because it
does not bind to it. We therefore propose that the loop is
intrinsically ﬂexible in TsUCH37 but can become ordered
under certain circumstances, such as under the constraints of
crystallographic packing.
It is possible that the corresponding loop segment in
hUCH37 is somewhat dynamic as well, but it appears to be
signiﬁcantly more ﬂexible in TsUCH37. The signiﬁcance of this
diﬀerence in dynamics between the two proteins is not clear at
the moment. Intriguingly, the loop’s dynamic behavior appears
to have an eﬀect on the conformation of a tryptophan residue
(Trp55) adjacent to the active site (Figure S2 of the Supporting
Information). This tryptophan is conserved among Schizosaccharomyces pombe (Sp), Ts, and human UCH37 (Figure S3

Figure 3. Secondary structures of TsUCH37 constructs.
TsUCH37ΔC46−UbVME and TsUCH37cat−UbVME complexes are
superposed with α-helices and 310-helices colored pale yellow, β-sheets
blue, loops green, and UbVME orange. Arrows indicate where the
TsUCH37ΔC46−UbVME structure lacks density, compared to the
TsUCH37cat−UbVME structure, from residue 57 to 71.

the notion that the dimer observed in the TsUCH37cat−
UbVME structure is a crystallographic dimer and may not exist
in solution. The two copies of the complex in the dimer
observed in the crystals of the TsUCH37cat−UbVME complex
have very similar structures with an rmsd of 0.39 Å between Cα
atoms. We will therefore focus on one of them in discussions
presented below.
Overall Structure of the UCH Domain of TsUCH37.
The overall structure of the TsUCH37 catalytic domain is
similar to that of other structurally characterized UCH
enzymes.49,50,73 It has the classical αβα fold, in which a central
six-stranded β-sheet is surrounded by six α-helices, ﬁve on one
side (α1−α5) and one on the other (α6) (Figure 3). The
3569
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Figure 4. ULD−ubiquitin interactions. (a) Sequence alignment of the ULD of UCH37 highlighting conserved residues in UCH37 homologues.
Glu265 and Asn272 (according to Ts numbering) are absolutely conserved (highlighted in red). (b) Superposition of the TsUCH37ΔC46−UbVME
complex (ULD colored olive and UbVME orange), human UCH37 (ULD colored purple, PDB entry 3IHR), and TsUCH37 with the entire ULD
modeled (cyan) based on the structure of the ULD in human UCH37. The model was generated using SwissModel and MD simulation (please see
Materials and Methods). This model is taken from a snapshot collected at 1.3 ns during a 2 ns MD simulation run. (c) Structure of the TsUCH37−
ubiquitin complex with the entire ULD modeled as shown in panel b, showing that the conserved residues of the ULD could make additional
contacts with ubiquitin. The regions marked i and ii are expanded in the panels below. The UCH domain is colored gray.

of the Supporting Information). In the TsUCH37ΔC46−
UbVME complex, Trp55 makes contact with the OMe group
of the suicide inhibitor, which in the actual substrate (a
ubiquitinated protein or the diubiquitin motif of a polyubiquitin
chain) would be replaced by the hydrocarbon portion of the
isopeptide-linked lysine side chain (Figure 1a). The same
residue in the TsUCH37cat−UbVME complex shows a diﬀerent
orientation with respect to the OMe group and appears to have
adopted a more open position for interaction with the
isopeptide unit (Figure S2 of the Supporting Information).
Therefore, Trp55 not only may provide important contacts
with the isopeptide link to hold it in place near the active site
but also may confer a certain plasticity to the active site of
UCH37, which may be useful for an induced-ﬁt type of
engagement with the substrate.
As stated before, in the TsUCH37ΔC46−UbVME structure,
we are able to visualize 40 additional amino acids after the
UCH domain, the ﬁrst 41 amino acids (residues 223−263) of
the ULD in TsUCH37. The polypeptide chain, after emerging
from the C-terminus of the UCH domain, adopts a helical
structure of six turns (α7), takes a U-turn, and then continues
as a helix (α8). α7 and α8 are arranged as a helix−turn−helix
motif with a number of interhelical contacts, and this motif
adopts a similar orientation with respect to the UCH domain as
observed in hUCH37 (Figures 3 and 4b).57 The only diﬀerence
in this motif between TsUCH37 and hUCH37 is that it is
somewhat shorter in the former. The ULD in TsUCH37
appears to have a proteolytically susceptible region after
Ala263, perhaps immediately following it, producing the Cterminal truncation we are observing here. When we model the
missing part of the ULD, using the structure of hUCH37 as a
template (see Materials and Methods), it is apparent that α8
could have continued on after the cleavage site (Figure 4b)
almost as a long helix all the way up to residue 285, except for
an interruption at Arg268 where four successive residues,

including the arginine, adopt nonhelical dihedral angles
producing a kink (a kink featuring equivalent residues is also
seen in the template structure). As expected from the hUCH37
structure, the model shows that after the interruption, the helix
would terminate at or near amino acid 285 (Figure 4), where
the polypeptide chain reverses its direction as a turn segment
that appears to cap the C-terminus of the helix. The putative
KEKE motif was not modeled because it is absent in the
template structure. Interestingly, the structure of the
TsUCH37ΔC46−UbVME complex reveals side chains from α8
making contact with ubiquitin, speciﬁcally with its Lys48
residue, an interaction that may explain the distal end speciﬁcity
displayed by UCH37 (discussed in more detail below). Also,
the side chains from the modeled part of the ULD, missing in
our structure, appear to present themselves for additional
contacts with ubiquitin. Indeed, the two most conserved
residues in the ULD, Glu265 and Asn272, are facing ubiquitin
and lie within contact distances (Figure 4c). Thus, it is possible
that they may actually bind to ubiquitin. Alternatively, in
contrast to what is predicted by the model, these residues may
be used for making contact with Rpn13, explaining why they
are conserved.
Active-Site Geometry. The catalytic triad in this cysteine
protease assumes a canonical arrangement in the ubiquitinbound complex. The distance between the catalytic cysteine
and histidine is 3.9 Å (Nδ−Sγ distance) in both structures, and
that between the histidine and aspartate is 2.8 Å (Nε−Oδ) in
the TsUCH37 cat −UbVME complex and 2.9 Å in the
TsUCH37ΔC46−UbVME complex. The distance between the
CεH group of the catalytic histidine and the side chain carbonyl
oxygen of the oxyanion stabilizing glutamine (Gln79) is 3.3 Å
in the TsUCH37cat−UbVME complex and 3.1 Å in the
TsUCH37ΔC46−UbVME complex, suggesting a signiﬁcant
CH···O interaction between them, an interaction seen in
other cysteine proteases as well.75 We were unable to crystallize
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Figure 5. Recognition of ubiquitin by TsUCH37. (a) Surface rendering of TsUCH37cat (cyan) with ubiquitin binding regions highlighted. The distal
site is colored yellow and the active-site cysteine red, and resolved portions of the crossover loop are colored pink. (b) Surface rendering of
TsUCH37ΔC46 (green) with ubiquitin binding regions highlighted as in panel a, except with additional C-terminal tail ubiquitin binding residues
colored blue. (c) Interactions near the active-site cleft with the C-terminal hexapeptide tail of ubiquitin. UbVME residues are colored orange,
TsUCH37 residues teal, and human UCH37 residues purple. (d) Interactions of Arg72 of ubiquitin with surrounding residues of TsUCH37cat.
Density from the 2Fo − Fc map is contoured at 1σ (blue mesh). (e) UCH37 distal-site binding residues, with TsUCH37 colored teal and human
UCH37 purple. (f) Ile44 patch interacting residues, with UbVME colored orange, TsUCH37 teal, and human UCH37 purple. Waters involved in
binding are also shown, enveloped with density from the 2Fo − Fc map contoured at 1σ. Sequence alignment of this region in TsUCH37 compared
to human UCH37 is shown as an inset. (g) Active site of TsUCH37 (teal), showing the catalytic residues, compared to human UCH37 (purple),
with UbVME colored orange.

the apo form of either TsUCH37cat or TsUCH37ΔC46. In its
place, we use the structure of apo human UCH37 to gain
insight into structural changes in the active-site region that may
occur upon ubiquitin binding.57,58 Comparison with the
structures of human UCH37 reveals that the catalytic cysteine
has changed its orientation, going from the apo form to the
ubiquitin-bound form, adopting a more productive orientation
in the latter, an orientation in which the catalytic cysteine’s side
chain faces the catalytic cleft (Figure 5g). This analysis suggests
that UCH37 exists in an unproductive form in the absence of

ubiquitin, with the catalytic thiol facing the interior of the
protein rather than the open space in the catalytic cleft,58 but is
induced to adopt a more productive form upon its binding.
Thus, UCH37 may oﬀer yet another example of a UCH DUB
that undergoes substrate-induced reorganization to a more
productive form.48,76
Crossover Loop Flexibility. A common structural feature
present in all UCH enzymes is the crossover loop, which in
TsUCH37 spans residues 141−157 (connecting α5 with β3). It
straddles the active-site cleft as a ﬂexible loop and is known to
3571
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(see Figure S4 of the Supporting Information). Many of the
active-site interactions observed in the ubiquitin-bound
structures of UCHL1, UCHL3, PfUCHL3, and Yuh1 are
conserved in both TsUCH37 structures. Additionally, those
residues surrounding the C-terminal hexapeptide tail of
ubiquitin are strongly conserved between the Ts and human
protein (Figure 5c).
The interactions at the active-site cleft appear to be necessary
for precise cleavage at the terminal glycine residue of ubiquitin,
while the distal site provides additional interaction to stabilize
the enzyme−substrate complex (Figure 5e,f). The distal site
engages the N-terminal β-hairpin of ubiquitin, which docks by
utilizing interactions primarily involving the two-residue β-turn
segment, Leu8 and Thr9 of ubiquitin. These interactions are
mostly hydrophobic in nature, involving van der Waals contact
of Leu8 and Thr9 with Val35, Leu36, Ile206, Phe216, and
Leu218, residues that constitute the surface-exposed hydrophobic crevice that is the distal site. Leu36, Ile206, Phe216, and
Leu218 are conserved among Sp, Ts, Pf, and human UCH37
(Figure S3 of the Supporting Information), suggesting the
importance of distal-site binding in enzyme−substrate recognition.
Ile44 of ubiquitin, a residue widely used in recognition by
ubiquitin-binding proteins, including DUBs, is seen making van
der Waals contacts with Val34 on a greasy loop in TsUCH37,
residues 34−36 (residues Val35 and Leu36 extend into the
distal-site pocket) (Figure 5f). A similar motif is used in other
UCH enzymes to bind to Ile44 of ubiquitin. Val34 of
TsUCH37 also makes contacts with His68 and Val70, which,
together with Ile44 and Leu8 from the N-terminal β-hairpin
turn, form the so-called Ile44 patch on ubiquitin. Thus, the
binding potential of the Ile44 patch on ubiquitin appears to be
fully satisﬁed in structures of the two complexes presented here,
with each residue in the patch making at least one contact with
the enzyme. The structural data presented here are supported
by previously reported mutational analysis of the PA700
isopeptidase. Replacing Ile44 and Leu8 from the Ile44 patch
with alanine in the distal ubiquitin of a diubiquitin substrate
results in signiﬁcantly impaired catalysis with no detectable
hydrolysis product.45 Val34 and Val35 are replaced with
tryptophan and serine, respectively, going from Ts to human
UCH37 (Figure 5f) (Val34 provides additional contacts with
Val70 of UbVME). These residues also show variability among
other UCH family members. Subtle diﬀerences in the Ile44
patch-binding residues could be one of the contributing factors
in the diﬀerence in KM between human and Ts UCH37,
especially as most of the residues at the active site are conserved
between the two.
There appear to be no striking conformational changes
between the ubiquitin-bound form of TsUCH37 and apo
hUCH37 except for the aforementioned reorientation of the
catalytic cysteine. However, we cannot rule out the possibility
that signiﬁcant conformational changes might have occurred as
a result of ubiquitin binding in the Ts enzyme because we could
not crystallize its apo form.
Ubiquitin Binding by the ULD. As mentioned earlier, the
ULD of hUCH37 was thought to have an inhibitory role,
presumably by folding onto the catalytic domain and
obstructing substrate binding.37 In contrast, the structure of
the TsUCH37ΔC46−UbVME complex provides crystallographic
evidence that the ULD can actually contribute to ubiquitin
binding and therefore can play a productive role in catalysis.
Arg261 and Tyr262 on α8 of the ULD approach ubiquitin to

provide steric constraint, limiting the size of the leaving group
at the C-terminus of ubiquitin.74,77 Accordingly, UCH enzymes,
such as UCHL1 and UCHL3, can cleave only small leaving
groups from the C-terminus of ubiquitin, not large proteins or
another ubiquitin.47 However, UCH37 is known to cleave
diubiquitin (and polyubiquitin chains), but only when it is
associated with the RP, being activated upon binding to its
protein cofactor, Rpn13.37 All previously determined structures
of UCH enzymes bound to ubiquitin have shown a resolved
crossover loop, which makes contact with at least one residue
from the C-terminal tail of ubiquitin. In the apo form of
UCHL3, the closest homologue of UCH37, the loop is
disordered but becomes ordered when ubiquitin is bound.48,50
The ubiquitin-bound structures of PfUCHL3 and the yeast
ubiquitin hydrolase Yuh1 show an ordered crossover loop
making contacts with side chains on the C-terminal tail of
ubiquitin.73,78 In contrast, the structures of the TsUCH37−
UbVME constructs present the only examples so far of a UCH
DUB in which the crossover loop is still disordered even after
ubiquitin is bound, indicating that the loop is ﬂexible and does
not contribute to ubiquitin binding. A small network of van der
Waals interactions and hydrogen bonds seem to stabilize part of
the crossover loop (residues 152−157) in a short helical
conformation in the structure of the TsUCH37cat−UbVME
complex, but the same segment in the TsUCH37ΔC46−UbVME
structure is disordered and hence not visible, supporting
dynamic sampling of conformations by this loop. The
observation that the crossover loop is ﬂexible despite the
bound ubiquitin may be related to its activation by its
proteasome cofactor Rpn13.37 By not engaging with ubiquitin,
the loop is available to freely interact with the cofactor, which
may stabilize it in a conformation that leaves the active site
maximally open to accommodate the isopeptide bond between
two ubiquitins or between ubiquitin and an acceptor protein.
Interactions with Ubiquitin. The interaction of UbVME
with the TsUCH37cat UCH domain buries a total of 2355 Å2 of
solvent accessible surface area, a value comparable to the
amount buried in other UCH domain ubiquitin complexes (the
buried accessible surface area in the TsUCH37ΔC46−UbVME
complex is 2479 Å2).48,76 The interaction is predominantly
localized at two areas on TsUCH37, the active-site cleft and the
distal site (Figure 5a,b) The active-site cleft engages the Cterminal hexapeptide segment, Leu71ArgLeuArgGly-Gly76VME,
of UbVME with numerous intermolecular contacts that include
van der Waals, hydrogen bonding, electrostatic, and watermediated interactions (Figure 5c). This segment sits in the
active-site cleft with an extended conformation to maximize
interactions with both backbone and side chain atoms of nearby
residues of the enzyme. As seen in other UCH structures, the
narrowest part of the active-site cleft surrounds the terminal
Gly-Gly motif, with the last Gly (GlyVME in this case) being
placed immediately adjacent to the Sγ atom of the catalytic
cysteine, precisely located for nucleophilic attack on the scissile
peptide bond (Figure 5a,b). It is interesting to note that Arg72
of UbVME is engaged in at least three major interactions
(Figure 5d), suggesting that it contributes signiﬁcantly to
stabilizing the enzyme−substrate complex. The interactions
with Arg72 imply that TsUCH37 will ﬁnd NEDD8 (neural
precursor cell expressed, developmentally downregulated 8, a
structurally similar ubiquitin-like protein modiﬁer with a
sequence that is 60% identical with that of ubiquitin) as a
poorer substrate because this arginine is replaced with alanine
in NEDD8. Indeed, TsUCH37 does not cleave NEDD8-AMC
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Figure 6. ULD of TsUCH37 binding to ubiquitin. (a) TsUCH37ΔC46 (olive) ULD residues interacting with UbVME (orange). The inset shows
interactions of Arg261 and Tyr262 with UbVME, as well as the intramolecular salt bridge formed between Lys48 and Glu51 of ubiquitin. Density
rendered from the 2Fo − Fc map contoured to 0.7σ. (b−e) Comparison of the Lys48−Glu51 distances in ubiquitin observed in other DUB−
ubiquitin structures. (b) Lys48 and Glu51 form a 3.7 Å salt bridge in the TsUCH37ΔC46−UbVME structure (olive), but not in the TsUCH37cat−
UbVME structure (9.9 Å). (c) The same distance in all other UCH−ubiquitin structures is ≥9 Å: UCHL3−UbVME (yellow, PDB entry 1XD3),
UCHL1−UbVME (red, PDB entry 3KW5), Yuh1−Ubal (pink, PDB entry 1CMX), PfUCHL3−UbVME (purple, PDB entry 2WDT), and
TsUCH37cat−UbVME (teal). (d) The same distance is 8.7 Å in the Otu1−ubiquitin structure (dark red, PDB entry 3BY4) and 6.0 Å in the DUBA−
Ubal structure (pale yellow, PDB entry 3TMP). (e) The same distance is 10 Å in the HAUSP/USP7−Ubal structure (blue, PDB entry 1NBF) and
10.9 Å in the USP14−Ubal structure (brown, PDB entry 2AYO).

engage in van der Waals contact with of three of its side chains,
Lys48 (with Arg261) and Gln49 and Arg72 (both with Tyr262)
(Figure 6). Most notably, Arg261 is oriented in such a way to
engage in close van der Waals contact with the hydrocarbon
portion of the Lys48 side chain, forcing it to adopt an unusual
conformation that allows an intramolecular salt bridge
interaction with Glu51. This interaction is not observed in
any of the 39 other ubiquitin-bound DUB structures currently
found in the PDB, catalogued in Table 3; the Lys48−Glu51
distance is greater than 5.8 Å in all. Figure 6b shows the
orientation of the same lysine in the TsUCH37cat−UbVME
complex. Clearly, the orientation is diﬀerent in this structure,
and the intramolecular salt bridge in ubiquitin is absent,
suggesting that Arg261 of the ULD plays a role in inducing the
unusual orientation of Lys48 of ubiquitin. Arg261 is conserved
among Sp, Ts, and human UCH37 (Figure 7) but is replaced
with leucine in PfUCH37 (also known as PfUCH54). Tyr262 is
conserved in human and Ts forms but is substituted with
tryptophan in Sp and PfUCH37. Inspection of the structure
reveals that the van der Waals contact with Lys48 is still feasible
with leucine in place of arginine and tryptophan can
conservatively replace tyrosine as well. Thus, it is likely that

ULD binding with Lys48 and subsequent formation of the
intramolecular salt bridge we are observing here are conserved
features of UCH37 in general.
UCH37, as a part of PA700, is known to selectively cleave
polyubiquitin chains from the very distal end, sequentially
removing one ubiquitin at a time.38 The structural basis of this
exo cleavage speciﬁcity is not yet known. The unique
orientation of Lys48 stabilized by Arg261 leading to the
intramolecular salt bridge may explain this selectivity. We
propose that although a similar type of interaction between
Arg261 and ubiquitin’s Lys48 is possible with an internal
ubiquitin, the intramolecular salt bridge will be absent in this
case because the amino group of the lysine is acylated and
hence not charged. Thus, it is the lack of an additional
interaction with an internal ubiquitin that makes binding to
Lys48 of the terminal ubiquitin more favored, hence the exo
selectivity.

■

DISCUSSION

UCH37 is a proteasome-associated UCH DUB known to have
polyubiquitin chain-editing function. It preferentially cleaves
the chain from its very distal tip.38 Such a function might rescue
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of which is not understood. We report here the structure of two
constructs of UCH37 from the infectious helminth T. spiralis
(Ts) bound to the suicide inhibitor UbVME. This work
constitutes the ﬁrst structural analysis of a ubiquitin pathway
protein in the organism showing how ubiquitin is recognized by
this UCH family DUB in Ts. The structures reveal striking
conservation of the ubiquitin binding mode among UCH
DUBs, from lower eukaryotes to human (Figure S5 of the
Supporting Information). It also shows important structural
diﬀerences between other UCH DUBs, such as UCHL1 and
UCHL3, some of which could be used for the specialized
function of UCH37. While revealing interesting diﬀerences, the
Ts structures provide a number of details that may also hold
true for the human enzyme, advancing our understanding of
UCH37 in general.
The active-site cysteine may undergo ubiquitin-mediated
reorientation to a more productive form (Figure 5g), making
UCH37 yet another example of a UCH DUB that shows
regulation of activity by ubiquitin, a feature that may provide
selectivity to this group of cysteine proteases. Structures of the
two constructs reveal invariant parts of the enzyme, likely less
dynamic parts, while also revealing parts that are more dynamic
in nature, such as the segment of residues 57−71 and Trp55.
Future studies should reveal the role of such dynamic parts in
catalysis or regulation thereof.
Importantly, the structure of the construct with the
additional 40 amino acids after the UCH domain reveals that
the ULD could contribute to ubiquitin binding (Figures 4 and
6), an unexpected ﬁnding because it was thought to be
inhibitory in the human enzyme.37 The interaction of Arg261
on the ULD appears to engage Lys48 of the distal ubiquitin in a
way that would be energetically most favored with the very
terminal ubiquitin in a polyubiquitin chain, possibly explaining
the exo speciﬁcity displayed by mammalian UCH37. These
structural data are consistent with previously reported mutational analysis probing substrate speciﬁcity of the PA700
isopeptidase: mutation of Lys48 to cysteine on the distal
ubiquitin of a diubiquitin substrate results in severely impaired
catalysis.45 Apart from the broad agreement with the
aforementioned experimental work, this observation of the
intramolecular Lys48−Glu51 salt bridge in the distal ubiquitin,
apparently induced by Arg261, is purely crystallographic at this
point, although it seems unlikely that lattice forces have
anything to do with it. Even if the opposite is true, the fact that
such interactions are physiologically relevant cannot be ignored.
The lack of an intramolecular Lys48−Glu51 salt bridge in any
other ubiquitin-bound DUB structures to date (Table 3) makes
this unusual interaction more intriguing, and worth additional
study. This observation therefore lays the structural groundwork for future mutational analysis aimed at validating their
existence in solution and their role in substrate speciﬁcity.
It is interesting to note that a salt bridge interaction, albeit an
intermolecular one, involving Lys48 of ubiquitin and an acidic
side chain of the enzyme is also seen in the structure of USP7
bound to ubiquitin aldehyde (the Lys48 side chain of the distal
ubiquitin is interacting with Asp305 and Glu308 of USP7).79
Such bifurcated salt bridges will perhaps contribute substantially to the binding of the enzyme to distal ubiquitin in a K48linked chain, based on which one may predict that USP7 will
also exhibit exo speciﬁcity. This needs to be examined.
Preferential cleavage from the very distal tip of a Lys48-linked
polyubiquitin chain may be a feature common to DUBs that
work on chains of this topology. Lys48-linked chains are known

Table 3. Lys48−Glu51 Distances for All DUB−Ubiquitin
Complexes
PDB
entry
1XD3
1CMX
2WDT
3IFW
3KVF
3KW5
3TMP
2Y5B
1NBF
2AYO
3MHS
2HD5
2G45
2J7Q
3V6E
3V6C
3IHP
3MTN
3IT3
3N3K
3NHE
2IBI
4IUM
3ZNH
4I6L
3PT2
4HXD
3BY4
3PRM
3PRP
3C0R
4DHZ
4DHJ
4DDI
4DDG
3PHW
3O65
2JRI
2ZNV

DUB−ubiquitin complex
UCH Family
UCHL3−UbVME
YUH1−Ubal
PfUCHL3−UbVME
UCHL1 S18Y−UbVME
UCHL1 I93M−UbVME
UCHL1−UbVME
USP Family
DUBA−Ubal
USP21−linear diUbal
HAUSP−Ubal
USP14−Ubal
SAGA complex (UBP8)−Ubal
USP2, Ub
IsoT, Ub
M48 USP−UbVME
USP2, Ub variant
USP2, Ub variant
USP5, Ub covalent
USP21, ubiquitin-based USP21-speciﬁc
inhibitor
USP21, Ub covalent
USP8, covalent Ub-like variant
USP2a, Ub
USP2, Ub covalent
OTU Family
arterivirus papain-like protease 2, Ub
CCHF viral, Ub-propargyl
OTUB1, Ub
viral OTU, Ub
Nairovirus viral OTU, Ub
OTU, Ub
CCHF viral OTU, Ub
CCHF viral OTU, Ub
OTU, Ub
h/ceOTUB1-ubiquitin aldehydeUBC13∼Ub
ceOTUB1 ubiquitin aldehyde
UBC13∼Ub complex
OTUB1/UbcH5b∼Ub/Ub
OTUB1/UbcH5b∼Ub/Ub
OTU domain of CCHF virus, Ub
MJD Family
Ataxin-3-like, Ub
Ataxin 3, Ub
JAMM Family
AMSH-LP, Lys63-linked diubiquitin

Lys48−Glu51
distancea (Å)
9.1, 11.5
10.8
7.3, 9.6
8.7
12.3
13.1
8.3
7.8, 10.8, 6.6
10.0, 10.7
10.9
9.2
9.0
8.6, 8.9
9.9, 10.8
7.0
7.4
9.6, 6.3
8.5
7.4, 7.5, 7.4, 7.4
10.4
7.4
7.6
7.4
9.5
9.1
10.7
8.3, 10.1
6.0
9.5, 10.0
10.3, 10.9
8.4
9.2, 8.8
11.4, 8.5, 6.9, 11.8, 9.8,
10.1
7.5, 12.6, 12.6, 7.5,
12.6, 7.5
11.3, 7.1, 8.0
7.6, 7.2, 9.0, 5.8
9.6, 11.4, 12.8, 11.5
12.3, 12.9
9.0, 8.3, 11.9, 11.3

a

Multiple distance entries refer to those in the other subunits of the
crystallographic asymmetric unit.

certain substrates from being committed to further downstream
action of the proteasome.38 It is also possible that certain
substrates carry inappropriate polyubiquitin tags that are not
optimal for their degradation. The chain-editing function might
be essential for releasing these substrates to clear up ubiquitin
receptors for binding to productive substrates. A regulator of
proteasome function, it is itself regulated by binding to the
proteasome: UCH37 is activated upon binding to Rpn13, a
subunit of PA700 (the 19S proteasome or RP), the mechanism
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Figure 7. Sequence alignment of TsUCH37 and other homologues: human UCH37, S. pombe Uch2, and Plasmodium falciparum UCH54. Secondary
structures for the two TsUCH37 structures are annotated above (e.g., α1, α-helix 1; β1, β-sheet 1; η1, 310-helix 1). α2′ and η2 are not resolved in the
TsUCH37ΔC46−UbVME structure, and helices α7 and α8 are not present in the TsUCH37cat−UbVME construct.

to adopt a compact structure.80 However, the terminal
ubiquitin, being less packed than the internal ones (packed
from both sides), is more likely to fray and be susceptible to
DUB cleavage for stereochemical reasons. Certain DUBs may
have evolved a mechanism for grabbing onto those fraying ends
and start disassembling chains from there. There may be other
DUBs that prefer internal ubiquitins, or the terminal ones on
the other extreme end of the chain, such as isopeptidase-T
(USP5),81 and there may be some with no preference at all.
The structure of AMSH-LP (a Lys63-linked chain-speciﬁc
DUB) in complex with Lys63-linked diubiquitin shows that
Lys63 on the distal ubiquitin is not engaged by the enzyme,
suggesting it is unlikely to show any preference between the
terminal and internal cleavage sites.82 This is consistent with
the structure of a Lys63-linked chain, which adopts a more
extended conformation in crystals and perhaps in solution as
well.83−85 Future structural studies should reveal more details
explaining exo and endo speciﬁcity seen in certain DUBs.
The structural analysis, combined with MD simulation,
shows the contribution of the ULD in ubiquitin binding. In
theory, certain residues in TsUCH37’s ULD, missing in our
structure, also appear to be correctly positioned for contacting

ubiquitin. Notably, the modeling study provides a possible
explanation of why Glu265 and Asn272 are so strictly
conserved in UCH37 from diﬀerent organisms, with virtually
no exception. Contributing to ubiquitin binding, as suggested
by our modeling studies, may be one of the functional
constraints underlying the conservation of the amino acids,
although one cannot rule out whether binding to other proteins
such as Rpn13 may be involved. It should be noted that Bap1, a
UCH DUB mutated in several cancers, also features a
ULD.70,71,86 Like UCH37, Bap1 becomes activated upon
binding to a larger protein complex, demonstrated with the
Drosophila orthologue, Calypso, binding to the polycomb
repressor DUB complex.87 Interestingly, the putative ubiquitinbinding residues of the ULD of UCH37 are also conserved in
Bap1 (data not shown), suggesting a role in ubiquitin binding
for Bap1’s ULD as well (in some Bap1 orthologues, the
glutamate corresponding to TsUCH37’s Glu265 is replaced
with an aspartate). However, human Bap1 has a linker of
approximately 300 amino acids separating the UCH domain
and its ULD. It will be interesting to see how the ULD
positions itself to bind ubiquitin, if it does. Of more interest is
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knowing whether the ULD has independent ability to bind to
ubiquitin.
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Nonlinear optical (NLO) instrumentation has been integrated with synchrotron
X-ray diffraction (XRD) for combined single-platform analysis, initially
targeting applications for automated crystal centering. Second-harmonicgeneration microscopy and two-photon-excited ultraviolet ﬂuorescence microscopy were evaluated for crystal detection and assessed by X-ray raster
scanning. Two optical designs were constructed and characterized; one
positioned downstream of the sample and one integrated into the upstream
optical path of the diffractometer. Both instruments enabled protein crystal
identiﬁcation with integration times between 80 and 150 ms per pixel,
representing a  103–104-fold reduction in the per-pixel exposure time relative
to X-ray raster scanning. Quantitative centering and analysis of phenylalanine
hydroxylase from Chromobacterium violaceum cPAH, Trichinella spiralis
deubiquitinating enzyme TsUCH37, human -opioid receptor complex kORT4L produced in lipidic cubic phase (LCP), intimin prepared in LCP, and cellulose samples were performed by collecting multiple NLO images. The
crystalline samples were characterized by single-crystal diffraction patterns,
while -cellulose was characterized by ﬁber diffraction. Good agreement was
observed between the sample positions identiﬁed by NLO and XRD raster
measurements for all samples studied.
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1. Introduction
The high photon ﬂux and energy tunability of synchrotron
radiation sources have made them indispensable tools for
X-ray analysis, with applications spanning protein structure
determination through materials science and nanotechnology
(Rasmussen et al., 2011; Moukhametzianov et al., 2008; Bates
et al., 2006; Berger et al., 2010; Dauter, 2006; Ihee et al., 2010;
le Maire et al., 2011; Parker et al., 2006; Riekel et al., 2005).
The increasing drive toward tighter focusing has enabled
structure determination on ever-smaller crystals and subdomains within materials, but presents growing challenges for
reliable crystal centering. These challenges are particularly
relevant for protein crystal diffraction, in which the drive
J. Synchrotron Rad. (2013). 20, 531–540

toward fully automated X-ray diffraction analysis at
synchrotron sources has introduced bottlenecks in sample
positioning (Andrey et al., 2004; Moukhametzianov et al., 2008;
Pothineni et al., 2006; Aishima et al., 2010; Cherezov et al.,
2009; Stepanov et al., 2011a). Diffraction-quality protein
crystals are typically obtained through crystallization screenings, followed by optimization, and then are placed into cryoloops, which are ﬂash-cooled in liquid nitrogen to reduce
X-ray damage and aid in sample handling (Dobrianov et al.,
1999; Karain et al., 2002). High-throughput methods for
automated crystal positioning are frustrated by complications
of reliable centering of smaller and smaller protein crystals
within more complex and turbid matrices. The current most
reliable methods for crystal centering involve rastering the
doi:10.1107/S0909049513007942
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sample using a focused X-ray beam (Accardo et al., 2010;
Hilgart et al., 2011; Cherezov et al., 2009; Stepanov et al., 2011a;
Aishima et al., 2010; Song et al., 2007). From the resulting
X-ray diffraction images recorded as a function of sample
position in the beam, protein crystals are centered based on
the locations of strongest Bragg-like diffraction. X-ray ﬂuorescence raster is also relatively fast, but it requires a convenient X-ray ﬂuorescent element to be present in the crystal
(Stepanov et al., 2011a).
While generally successful, X-ray raster scanning suffers
from several limitations. First, the method is relatively slow,
often utilizing > 2 s per pixel (raster cell), corresponding to
analysis times from several minutes up to an hour depending
on the number of cells in the raster grid and on the exposure
time (Aishima et al., 2010). Rastering is commonly performed
ﬁrst with a coarse grid, and then a ﬁner grid, to minimize the
number of cells, and to increase speed. The total pixel number
is in turn dependent on the size of the X-ray beam, the speed
of the detector and analysis, as well as the scanned size of the
cryo-loop and the crystal itself (Cherezov et al., 2009; Song
et al., 2007). Recent advances in diffraction image read times
using single-photon-counting arrays (pixel array detectors)
(Broennimann et al., 2006), allowing integration times as low
as 2 ms per image (Aishima et al., 2010), can signiﬁcantly
reduce the time frame for raster scanning measurements.
However, the time required for raster scanning will still ultimately be limited by the collective times required to obtain
sufﬁcient signal to noise (S/N) in a given pixel, to translate the
sample through the X-ray source, and to reconstruct the
crystal positions based on automated analysis of the compiled
diffraction images. Diffraction is a relatively inefﬁcient process
with far more X-ray photons absorbed or inelastically scattered than detected for diffraction analysis, contributing to
sample damage, even under the cryogenic conditions typically
utilized. With small crystals or beams, incident X-ray intensities must be increased accordingly to achieve diffracted
intensities equivalent to those for large crystals, thereby
increasing absorbed X-ray dose and exacerbating damage.
Alternative methods for automated loop centering based on
optical imaging include bright-ﬁeld image analysis and ultraviolet ﬂuorescence (UVF) microscopy, which takes advantage
of intrinsic ﬂuorescent properties of protein crystals (Jain &
Stojanoff, 2007; Vernede et al., 2006; Pohl et al., 2004; Andrey
et al., 2004; Pothineni et al., 2006). However, algorithms for
protein crystal centering (e.g. based on crystal edge-ﬁnding
algorithms) are error-prone for microcrystals and turbid
matrices, such as lipidic cubic phase (LCP). Methods optimized for analysis within the mother liquor often prove
unreliable for a loop-mounted crystal, in part because algorithms often cannot easily distinguish between the loop,
features in the cryo-cooled mother-liquor and the crystal.
Furthermore, both bright-ﬁeld and UVF imaging are challenging to reliably implement in turbid matrices, where optical
scattering frustrates reliable crystal imaging. UVF also has
a potential disadvantage of inducing UV photodamage to
samples from long exposures, or in highly labile proteins, but
the exposure times required for imaging are typically short
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enough to minimize such effects (Vernede et al., 2006; Chen et
al., 2009; Nanao & Ravelli, 2006).
More recently, nonlinear optical imaging (NLO) methods
such as second-harmonic generation (SHG) and two-photonexcited UV ﬂuorescence (TPE-UVF) have emerged as viable
alternatives for high-contrast crystal visualization (Kissick et
al., 2010; Madden et al., 2011). SHG, or the frequency doubling
of light, is symmetry forbidden in disordered media (e.g.
amorphous protein aggregates or proteins in solution) but is
allowed for certain classes of crystals (Haupert & Simpson,
2011). Fortuitously, the chirality intrinsic to proteins typically
results in the adoption of SHG-active crystal classes. Recent
quantum chemical calculations suggest an SHG coverage of
approximately 84% of protein crystals in the Protein Crystal
Database using an optimized instrument (Haupert et al.,
2012). TPE-UVF provides a complimentary method to SHG
for protein crystal detection, with contrast dependent on the
presence of aromatic side-chains (primarily tryptophan),
independent of crystallinity. Crystals that are weakly active to
SHG imaging but contain ﬂuorescent amino acid residues can
be detected (Madden et al., 2011). Furthermore, TPE-UVF
can aid in distinguishing SHG-active small-molecule and salt
crystals from protein crystals.
The high selectivity for crystals and negligible background
from disordered protein aggregates typically produces highcontrast SHG images, which are highly compatible with
automated image analysis algorithms designed for protein
crystal detection and centering (Haupert & Simpson, 2011).
SHG measurements have recently enabled crystal detection
for diffraction centering using off-line instrumentation
(Kissick et al., 2013), in which protein crystals were ﬁrst
imaged under cryogenic conditions with an SHG microscope,
and then manually compared with diffraction images obtained
by X-ray raster scanning with good agreement. A major
beneﬁt of NLO instruments is the reduction in time required
to determine crystal locations with high contrast, as
measurements for an entire loop can be obtained in as little as
a few seconds, compared with tens of minutes routinely
required for X-ray raster imaging. The spatial resolution of
NLO instruments is also high ( 1–2 mm), whereas X-ray
diffraction (XRD) rastering with this type of resolution would
take substantially longer to scan an area equivalent to that of
the entire NLO image (> 72 h at 1 s per pixel for a 512  512
pixel image). Furthermore, reducing the reliance on X-ray
raster imaging would minimize X-ray-induced sample damage
(Hilgart et al., 2011; Ravelli & Garman, 2006).
By integrating SHG and TPE-UVF imaging directly into a
synchrotron X-ray diffraction beamline, the robotic controls,
automated positioning capabilities, cryogenics and other
beamline utilities of high-throughput synchrotron facilities can
be leveraged. However, the spatial constraints of a typical
synchrotron X-ray experimental hutch represent a nontrivial
hurdle for development of compatible NLO instrumentation.
Typical research NLO instruments occupy a large footprint
(an optical table approximately 120 cm  300 cm), far greater
than the space available on a typical beamline. In this
work, two complementary prototypes for an on-line compa-
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tible instrument combining synchrotron
XRD and NLO imaging are described.
Assessment of these systems was
performed by direct comparisons
between NLO images and those
obtained by X-ray diffraction rastering.

2. Experimental methods
Two separate instruments were
designed and constructed for integrating XRD and NLO imaging, each
with its own advantages and limitations.
The upstream version introduced the
incident light coaxial and parallel with
the direction of the X-ray beam path,
while the downstream system was
coaxial and anti-parallel. The upstream
version was designed to fully integrate
with the existing optical path, while the
downstream version was optimized for
high ﬂexibility and compatibility with
diverse beamline conﬁgurations. Both
systems were rated as Class I laser
systems on-site, with enclosed beam
paths, shutters and interlocks to ensure
Figure 1
(a) Schematic of the downstream NLO microscope; (b) schematic of the upstream NLO
no exposed collimated optical radiation.
microscope; (c) close-up view of the downstream NLO microscope, with the solid arrow
The integrated NLO microscopes were
representing incident laser propagation (red, 1060 nm) and dashed arrows representing the
installed at beamlines 23-ID-B and 23frequency-doubled signal (green, SHG at 530 nm); (d) close-up view of the upstream NLO
ID-D at the Advanced Photon Source
microscope, with solid arrows representing incident laser propagation (red, 1060 nm; green, 530 nm)
and dashed arrows representing the measured signal (green, SHG at 530 nm; blue, TPE-UVF).
(APS) at Argonne National Laboratory
in Argonne, IL, USA. A basic schematic
Focus, 8892-K). The scanning assembly consisted of a
of the instruments and beam paths as they were installed on
galvanometer mirror (Cambridge Technology, 6210H) and
the synchrotron beamline can be seen in Fig. 1. Detailed
resonant scanning mirror (Cambridge Technology, 1-003descriptions and photographs are provided.
3002509), controlling the beam position on the horizontal
2.1. Integrated nonlinear optical microscope designs
slow-scan and vertical fast-scan axes, respectively. The beam
was directed into a telocentric lens pair consisting of two
The upstream illumination NLO system was designed to sit
plano-convex lenses ( f = 75 mm and f = 250 mm) leading to an
above the existing instrumentation at GM/CA beamline 23additional 3.3 beam expansion after the scan head. The
ID-B at the APS, and couple directly into the existing optical
incident light then reﬂected off a dichroic mirror stack
path. A Fianium FemtoPower 1060 ultrafast ﬁber laser was
(Semrock, PBP01-529/23-25x36 and Chroma, 900dcsp)
utilized, producing  160 fs pulses centered around 1060 nm,
designed to reﬂect 1060 nm and s-polarized 530 nm incident
with a 50 MHz repetition rate, maximum power of 1.5 W,
light. The p-polarized component of the returning 530 nm light
allowing for a maximum power of  140 mW at the sample,
was transmitted by this same dichroic for epi-detected SHG
with 80% of the overall loss arising from the objective. The
(i.e. SHG detected in the backward direction through the same
Fianium source was composed of an oscillator coupled via a
objective as the incident light). High-reﬂectivity dichroic
1.5 m ﬁber to a dispersion compensator and free-space coupler
mirrors for both 1060 nm and 530 nm light (Semrock, FF550unit, with dimensions of approximately 15 cm  13 cm  8 cm.
Di01-25x36) delivered both wavelengths to the back aperture
A heated doubling crystal (Newlight Photonics Inc.,
of the 10 objective (Optem, 28-21-10), which was modiﬁed
SHG1663-IM, HTS 85141000) was permanently assembled in
with a  1.2 mm hole bored through the center to allow
the beam path, with the fundamental beam focused into the
X-ray access. In epi, the p-polarized SHG returning through
crystal with a plano-convex lens ( f = 35 mm) and collimated
the dichroic mirror was passed through a bandpass ﬁlter
with another plano-convex lens ( f = 100 mm) after the
set (Chroma, HQ530/30m and CVI, 03FCG567/KG3) and into
doubling crystal. The efﬁciency of SHG from the doubling
a compact photomultiplier tube (PMT) module (Hamamatsu,
crystal was controlled by either introducing or removing a
H10722-10). SHG and TPE-UVF were collected in the
1064 nm zero-order half-wave plate using a ﬂip mount (New
transmission direction by a plano-convex lens ( f = 25.4 mm)
J. Synchrotron Rad. (2013). 20, 531–540
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afﬁxed to a right-angle prism using optical epoxy (Norland
Optical Adhesive 63). Another plano-convex lens (f =
25.4 mm) coupled the detected light into a near-UV-compatible liquid light guide (Oriel Instruments, 77554) collimated
with a plano-convex lens (f = 25.4 mm) into the detection
assembly. Both the SHG and TPE-UVF were then reﬂected
off a primary dichroic beam splitter (Semrock, FF555-Di0325x36), then separated at a second dichroic beam splitter
(Chroma, z1064rdc-sp) for selective detection of SHG
(through Chroma, HQ530/30m and CVI, 03FCG567/KG3
ﬁlters) and TPE-UVF (through Semrock, SP01-532RS-25 and
FF01-440/SP-25 ﬁlters). Both the SHG and TPE-UVF were
focused onto the faces of the PMT modules (Hamamatsu,
H10722-10) by a plano-convex lens ( f = 60 mm) positioned
between the primary and secondary dichroic beam splitters.
Backlight illumination was achieved using an LED (ThorLabs,
MCWHL2) passing through the primary dichroic beam
splitter and into the liquid light guide. The illumination light
was then focused through the trans-SHG/TPE-UVF collection
optics and onto the sample.
The downstream NLO system was also designed with the
optical axis of the objective co-axial with the axis of X-ray
propagation [Figs. 1(a) and 1(b)], using a similar laser source.
The size constraints associated with this beamline, speciﬁcally
the restrictions imposed by the support structure of the
beamline and the area and instruments surrounding the
sample, limited the available footprint of the NLO system to
39 cm  19 cm. The scanning assembly was composed of dual
galvanometers (Cambridge Technologies, 6210HSM40B),
mounted in a two-dimensional galvo 30 mm cage cube
(Thorlabs, GCM002), with each scanning mirror rotating
along either the x or y axis. With the scan head inducing a 90
turn into the beam path, the incident light was directed
through a telocentric lens pair, mounted in a 30 mm cage cube,
and composed of an aspheric lens (f = 10 mm) and a planoconvex lens ( f = 50 mm), leading to a 5 beam expansion. The
incident light was then focused onto the sample by a longworking-distance IR 10 objective (Mitutoyo, NT46-403)
generating SHG at 530 nm. Up to 650 mW of 1064 nm light
could be delivered to the sample with this system with the use
of the IR objective (compared with 140 mW with the upstream
system). The SHG was detected in the epi-direction, collected
through the incident objective and reﬂected through a ﬁlter set
and onto a compact PMT module (Hamamatsu, H10722-10)
by a dichroic mirror (Omega Optical, 580DCLP) centered
around 532 nm and mounted in a rotatable kinematically
controlled cage cube platform. The SHG signal was detected
through a ﬁlter set composed of a KG3 (Thorlabs, FGS900)
and 530 nm ﬁlter (Chroma, z532/10x). Bright-ﬁeld images
were also collected in the epi-direction using a module
composed of an aspheric lens ( f = 20 mm) and a CMOS
camera (Thorlabs, DCC1645C), manually inserted when
bright-ﬁeld images were desired. Including the laser source,
the total footprint of the microscope was 25 cm  15 cm 
15 cm. The microscope was translated to the sample, at a
height of 1.4 m, to perform SHG detection and centering
measurements. The foundation of the microscope was a
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high-precision long-travel translation stage (Newport,
M-IMS300V), and its electronics box (Newport, ESP 300,
three-axis motion controller), capable of translating the laser
pulse-compressor/output coupler, the microscope and the
support structure to and from the sample between X-ray
measurements, corresponding to approximately 20 cm of
travel, with an absolute accuracy of 2 mm.
The electronics package was designed and constructed in
collaboration with the Jonathan Amy Facility for Chemical
Instrumentation at Purdue University (JAFCI). The electronics package integrated the electronics associated with the
microscope, including the power supplies, control boards and
data acquisition card (National Instruments), into a compact
housing for easy mounting and transport, with a footprint of
46 cm  61 cm  31 cm. Data were acquired as photon counts
using a gated multi-scalar card (Becker & Hickl, PMS-400a),
controlled using a custom-designed Labview program, which
was also written in collaboration with JAFCI. Data reconstruction and imaging were completed through ImageJ (NIH,
2011).
2.2. X-ray raster scan scheme

XRD analysis and NLO images were acquired on all
samples studied on 23-ID-B. Diffraction of kOR-T4L was
acquired with a 5 mm-diameter X-ray beam, 5  5 mm cell size,
12.0 keV X-ray beam, with 1 s exposure times, a photon ﬂux
of 2.7  1010 photons s 1 (full unattenuated beam) and a
detector distance of 300 mm. Diffraction of TsUCH37 was
acquired with a 10 mm-diameter X-ray beam, a 10  10 mm
cell, a photon ﬂux of 1.3  1010 photons s 1 (10-fold
attenuation) and detector distance of 300 mm. Diffraction of
-cellulose was acquired with a 10 mm-diameter X-ray beam,
a 10  10 mm X-ray beam with a photon ﬂux of 2.7 
109 photons s 1 (50-fold attenuation) and detector distance of
300 mm. The resulting NLO images and XRD raster
measurements were compared using ImageJ and JBluIce
(Hilgart et al., 2011), which employs DISTL (Zhang et al.,
2006), to assess the degree of correlation of the sample position within the loop. The boundaries of the raster grids and
raster cell sizes were deﬁned using the software GUI JBluIce
(Stepanov et al., 2011b). Bragg candidates, which estimate the
number of well-ordered reﬂections, were generated for each
X-ray diffraction image; they are shown color-coded in the
ﬁgures as unsmoothed XRD raster images. The X-ray beam
size was adjusted using a mini-beam collimator (Fischetti et al.,
2009).

3. Sample materials
Phenylalanine hydroxylase from Chromobacterium violaceum
(cPAH) was puriﬁed as a glutathione s-transferase (GST)
fusion protein. The GST tag was cleaved with PreScission
protease (GE Biosciences). For crystallization, cPAH was
concentrated to 10 mg ml 1 in a solution of 5 mM HEPES, pH
7.4. Crystals of cPAH were obtained at ambient temperature
utilizing hanging-drop vapor diffusion from solution 43 of
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Hampton Research’s PEG/Ion 2 screen [0.1 M Na-HEPES,
pH 7.0, 0.01 M magnesium chloride hexahydrate, 0.005 M
nickel (II) chloride hexahydrate and 15% w/v PEG 3350] with
8.3 mM hexammine cobalt (III) chloride and 8.3 mM guanidine hydrochloride as additives. Crystals were brieﬂy soaked
in 25% ethylene glycol and then ﬂash-cooled in liquid
nitrogen.
Crystals of human -opioid receptor in complex with an
antagonist JDTic were obtained as described by Wu et al.
(2012). Brieﬂy, the human -opioid receptor sequence was
modiﬁed by fusing T4 lysozyme (T4L) into intracellular loop 3
(Gly261–Arg263), performing N/C-terminal truncations
(Glu2Ala42, Arg359Val380) and introducing a single
point mutation Ile1353.29Leu. The resulting construct kORT4L was expressed in baculovirus infected sf9 insect cells.
Receptor was extracted from isolated membranes using
dodecylmaltoside/cholesterol
hemisuccinate
detergent
mixture, puriﬁed by metal-afﬁnity chromatography, and
concentrated to 40 mg ml 1. Lipidic cubic phase crystallization was performed as previously described (Caffrey &
Cherezov, 2009; Cherezov et al., 2004), by mixing protein
solution with 10% cholesterol in monoolein at 2/3 protein
solution/lipid ratio, and dispensing 50 nL protein laden LCP
boluses overlaid with 800 nL precipitant solutions in a 96-well
glass sandwich plate (Marienfeld) (Cherezov & Caffrey, 2003)
using a NT8-LCP crystallization robot (Formulatrix). Crystals
were obtained in 100 mM sodium citrate pH 5.8–6.4, 28–32%
(v/v) PEG 400, 350–450 mM potassium nitrate, and were
harvested directly from LCP matrix using MiTeGen micromounts and ﬂash-cooled in liquid nitrogen.
The catalytic domain of Trichinella spiralis deubiquitinating
enzyme UCH37 was expressed in E. coli as a GST-fused
construct, puriﬁed on a glutathione-agarose column,
complexed with ubiquitin vinyl methyl ester (UBVME), and
subsequently puriﬁed by ion-exchange chromatography.
Crystals of this complex, hereafter referred to simply as
TsUCH37-UbVME complex, were grown by hanging-drop
vapor diffusion in 3 M ammonium sulfate, 0.1 M bicine pH 9.0,
and 2 mM l-glutathione (mixture of reduced and oxidized)
over two days at room temperature.
The -cellulose was prepared from pulpwood that underwent both the Kraft process and subsequent mercerization
(Sixta et al., 2004; Takai & Colvin, 1978).
A construct encoding the membrane domain of E. coli
O157:H7 intimin was expressed, puriﬁed and crystallized as
described previously (Fairman et al., 2012). Brieﬂy, Int208-449
was expressed in the outer membranes of E. coli BL21(DE3)
cells, extracted with the detergent Elugent (Calbiochem), and
puriﬁed by Ni-NTA afﬁnity and anion-exchange chromatography using buffers containing dodecyl maltoside
(Anatrace). Size-exclusion chromatography was used as a ﬁnal
puriﬁcation step and served to exchange the detergent to
lauryl dimethyl amine oxide (LDAO, Anatrace) using a buffer
containing 50 mM Tris-HCl, pH 7.5, 200 mM NaCl, 0.01%
NaN3 and 0.05% LDAO. The protein was concentrated to
20 mg ml 1, heptanetriol was added at 3% w/v, and the solution was mixed with monoolein at a 2/3 protein-to-lipid ratio.
J. Synchrotron Rad. (2013). 20, 531–540

A Mosquito LCP robot (TTP Labtech) was used to dispense
100 nL protein–lipid droplets, overlaid with 750 nL well
solutions. Intimin crystals grew from 100 mM sodium citrate,
pH 4.5–5.5, 50–100 mM NaCl, 100–150 mM MgCl2 and 30–
34% PEG 400. Crystals were mounted directly from the LCP
mixture and ﬂash-cooled in liquid nitrogen.

4. Results and discussion
Data were acquired with both downstream and upstream
versions of the NLO instrument, and schematic representations along with photographs of the beam paths are shown
in Fig. 1.
Fig. 2 (acquired via the upstream system) shows a large
TsUCH37-UbVME crystal. Both the presence and position of
the crystal can be independently conﬁrmed with bright-ﬁeld
imaging (a), NLO microscopy and XRD measurements. Signal
intensities of the corresponding epi-SHG (b), transmissionSHG (c) and TPE-UVF (d) were measured and processed in
ImageJ. Although the crystal is visible using conventional
optical imaging approaches, NLO microscopy produced
substantial improvements in contrast compared with brightﬁeld imaging. An X-ray diffraction raster was acquired (e) and
a representative diffraction image is shown ( f ).
Intimin protein crystals in LCP were examined using the
upstream NLO system. In Fig. 3 the bright-ﬁeld image is
shown in (a), with the corresponding trans-SHG image (b),
and X-ray raster acquired with a 5  5 mm beam, conﬁrming
the presence of a protein crystal (c), with the spot having
greatest protein-like diffraction circled and the resulting
diffraction pattern provided (d). All protein crystals identiﬁed
by SHG and XRD were accurate for absolute position within
the resolution of the 5 mm X-ray beam.
In Fig. 4 (acquired via the upstream system) a bright-ﬁeld
image of a kOR-T4L crystal within frozen lipidic cubic phase
is shown (a). As often arises with lipidic mesophase crystallizations, the looped droplets exhibited high optical scattering
upon freezing that frustrated conventional bright-ﬁeld
imaging approaches for crystal positioning. Transmission SHG
(b) and TPE-UVF (c) images were acquired, exhibiting localized areas ( 2–5 mm) of signal within the loop, suggesting the
presence of a crystal. Crystals were conﬁrmed via a 5 mmdiameter X-ray beam and 5  5 mm cell X-ray raster scan (d),
in which several pixels exhibit weak, but detectable, diffraction with Bragg analysis consistent with the presence of a
protein crystal. Diffraction patterns for the brightest spot are
shown in Fig. 4(e). However, signal is observed in the transSHG and TPE-UVF images that does not correspond to areas
of protein-like diffraction in the X-ray raster image. This
signal discrepancy is tentatively attributed to protein crystals
that are too small to produce Bragg peaks by XRD, or to the
presence of other ordered materials arising in a false positive.
False negatives for particular focal planes were also observed,
in which analysis of the diffraction patterns obtained from the
raster image indicates the presence of protein-like diffraction
located in areas that did not exhibit substantial SHG or TPEUVF due to the ﬁnite depth of ﬁeld ( 25 mm). However,
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false positives. False positives can arise
using TPE-UVF if there is protein
aggregate located within the loop
because TPE-UVF probes the presence
of aromatic residues and is not crystal
speciﬁc. Salt crystals and protein
aggregates are common occurrences
with protein crystal growth, generating
false positives for SHG and TPE-UVF
measurements, respectively. Fortunately, most simple salts adopt SHGinactive centrosymmetric structures.
Complementary use of these two techniques can signiﬁcantly reduce the
likelihood of false positives and false
negatives.
Combined NLO imaging and XRD
was also applied to studies of -cellulose, which exhibits ﬁber-like diffraction. NLO measurements performed
on loop-mounted cellulose generated
moderate S/N for multiple ﬁbers within
Figure 2
the sample loop (Fig. 5, acquired via
(a) Bright-ﬁeld image of a T. spiralis UCH37 1-226/UbVME complex crystal ( 100 mm thick) and
the upstream system). Although ﬁber
the corresponding (b) epi-SHG, (c) trans-SHG, (d) TPE-UVF and (e) X-ray raster scan within the
300  300 mm box. ( f ) X-ray diffraction of a representative 10 mm-diameter area from (e). X-ray
diffraction was evident from the celluenergy: 12 keV; exposure time: 1 s; photon ﬂux: 2.7  109 photons s 1 (10-fold attenuation);
lose samples, the DISTL algorithm used
detector distance: 300 mm; maximum theoretical resolution: 2.25 Å. The large difference in the epiin raster scanning, which searches for
and trans-SHG signals is expected for thick samples owing to the difference in the forward and
discrete Bragg reﬂections or spots and
backward coherence length. The intensities of the two directions will approach equality as the
sample thickness approaches the backwards coherence length ( 100 nm). Scale bars are 100 mm.
not ﬁber diffraction, does not indicate
(Three darkened spots, apparent in this ﬁgure, arose from separate X-ray ‘burn tests’ to assess X-ray
these areas, but rather seems to show
damage, the results of which will be published in a future study.)
that no measurable sample is present.
Manual inspection of the individual
diffraction patterns was performed to discern the presence of
acquisition of multiple focal planes through samples has been
ﬁber diffraction.
observed to recover crystal locations more quantitatively (not
cPAH crystals ranging in size from 50 mm to 200 mm in
shown).
length were imaged with both the downstream instrument
In SHG measurements the possibility of false positives
with epi-only detection and X-ray raster scanning [Fig. S2
exists from other SHG-active structures. Most notably, some
(supplementary information)]. The locations of intense
salts commonly used in crystallization screening can adopt
protein-like Bragg diffraction typically agreed well with those
non-centrosymmetric SHG-active lattices and produce bright
of brightest epi-SHG for both large and small cPAH crystals
SHG. Alternatively, noncrystalline structures exhibiting
(e.g. Fig. S2). However, departures between the two were also
molecular ordering over distances signiﬁcantly greater than
observed. Several explanations for the differences were
the wavelength of light can also potentially produce false
considered. First, the presence of multiple crystalline domains
positives for SHG. An example of a false positive, from a
within the crystal (e.g. from twinning) may cause the diffracnoncentrosymmetric vanadate salt crystal, is shown in Fig. S1
tion spot total to deviate from indicating optimal protein
of the supplementary information1 in which a cryo-loop
ordering. Second, inhomogeneous optical scattering of the
containing a crystal grown in LCP was examined with the
incident or detected light can potentially impact the contrast
upstream NLO instrument, and yielded substantial signal in
through effects unrelated to the crystal SHG activity.
the epi- and transmission-SHG directions. X-ray raster scans
However, bright-ﬁeld images do not suggest substantial
suggested the presence of salt-like diffraction, in addition to
differences in optical transmissivity across the crystal that
ice diffraction, as there was ice present on the sample loop.
might have inﬂuenced contrast. Finally, NLO measurements
Key signatures for an SHG-active salt were found to be bright
probe a much narrower depth of ﬁeld than X-ray diffraction,
epi-SHG and little to no detectable TPE-UVF. These salt
which is penetrating. If a particular crystal was not positioned
crystal signatures can be exploited to reduce the likelihood of
within the depth of ﬁeld of the beam-scanning NLO microscope, the SHG efﬁciency will be substantially reduced or
1
Supplementary data for this paper are available from the IUCr electronic
entirely absent within the detection limits of the instrument.
archives (Reference: WA5051). Services for accessing these data are described
at the back of the journal.
Despite the quantitative discrepancies, the presence of SHG
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Figure 3
(a) Bright-ﬁeld for an intimin protein crystal generated in LCP with
corresponding (b) trans-SHG and (c) X-ray raster summary overlay
showing corrected Bragg-like reﬂection counts. (d) X-ray diffraction of
the 5 mm-diameter area corresponding to the red circles in each image,
with X-ray energy 12.0 keV, exposure time 1 s, photon ﬂux 2.7 
1010 photons s 1 (unattenuated beam), sample-to-detector distance of
300 mm, resulting in a maximum theoretical resolution of 2.25 Å. Scale
bars are 50 mm. Cross-hairs were added to (a) and (b) to assist in orienting
the ﬁeld of view with respect to the diffraction raster images.

signals above the background correlated with the areas of
the crystal generating a detectable protein-like diffraction,
providing preliminary conﬁrmation of the ability of the
downstream instrument to rapidly generate information for
crystal position as a complement to X-ray raster scanning.
The polyimide loops (MiTeGen) were found to undergo
noticeable deformation with less than 100 mW incident power
using the downstream system, whereas the nylon loops were
more robust, and were not damaged at these powers. No
noticeable damage could be induced in either loop types using
the upstream system during either SHG or TPE-UVF
measurements (120 mW and 90 mW, respectively). Several
mechanisms were considered for the observed laser-induced
damage to the polyimide loops when measured with the
downstream system. Previous studies suggest that damage
from multi-photon absorption and plasma formation was
found to be an important, if not dominant, mechanism for
damage in biological NLO imaging (Sacconi et al., 2006).
However, those measurements were performed under condiJ. Synchrotron Rad. (2013). 20, 531–540

Figure 4

(a) Bright-ﬁeld image of a membrane protein (human -opioid receptor
complex) crystal in lipidic cubic phase and the corresponding (b) transSHG and (c) TPE-UVF, with (d) an X-ray raster summary overlay
showing corrected Bragg-like reﬂection counts. (e) X-ray diffraction of
the 5 mm-diameter area corresponding to the red circles in each image.
X-ray energy: 12.0 keV; exposure time: 1 s; photon ﬂux: 2.7 
1010 photons s 1 (unattenuated beam); sample-to-detector distance:
300 mm; maximum theoretical resolution: 2.25 Å. Scale bars are 20 mm.
Cross-hairs were added to (b) and (c) to assist in orienting the ﬁelds of
view with respect to the bright-ﬁeld and diffraction raster images.

tions of tight focusing [high numerical aperture (NA)] and
on live cells/tissues. However, alternative mechanisms may
dominate in the present low-NA studies of puriﬁed protein
crystals maintained under cryogenic conditions. Local heating
was also considered as a possible damage mechanism, arising
from either one- or two-photon absorption of the incident
beam. The marked difference in damage susceptibilities
between the upstream and downstream systems is consistent
with this mechanism, differing notably in the use of a resonant
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Figure 5
(a) Bright-ﬁeld image of -cellulose ﬁbers and the corresponding (b) epiSHG and (c) trans-SHG images, all 300  300 mm. (d) X-ray diffraction of
a 10 mm-diameter area within the red circle of each image. X-ray energy:
12.0 keV; exposure time: 1 s; photon ﬂux: 2.7  1010 photons s 1
(unattenuated beam); sample-to-detector distance: 300 mm; maximum
theoretical resolution: 2.25 Å. Scale bars are 100 mm. Cross-hairs were
added to (b) and (c) to assist in orienting the ﬁelds of view with respect to
the bright-ﬁeld image.

8 kHz scan mirror for the upstream system and a galvanometer-driven mirror operating at 200 Hz on the downstream
system. Rapid beam-scanning using a resonant scanner
combined with long-wavelength (> 1 mm) incident light was
shown previously to have no detectable effect on crystal
diffraction quality using a variety of protein crystals, including
myoglobin crystals containing heme groups exhibiting strong
visible light absorption (Kissick et al., 2013). Myoglobin was
speciﬁcally chosen, as the color center was anticipated to be
highly susceptible to light-induced perturbation (Banerjee et
al., 1969). However, no statistically signiﬁcant structural
changes to the lattice were observed in laser-exposed versus
unexposed regions of single crystals (Kissick et al., 2013).
The susceptibility for damage using the polyimide loops
increased notably for TPE-UVF, as the optical transparency
was substantially reduced at 530 nm. Whereas loop absorption
is negligible at 1 mm for SHG, roughly 30% of the incident
530 nm light for TPE-UVF is absorbed by the standard
yellow-tinted polyimide loop material (MiTeGen, http://www.
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mitegen.com/). By positioning the loop to avoid the outer
turning points of the fast-scan mirror or blocking the beam at
those locations, no noticeable damage could be induced in the
polyimide loops during TPE-UVF imaging.
Both of the NLO imaging systems presented in this paper
have strengths and limitations, and either could be utilized as
a method for locating and centering protein crystals on a
synchrotron beamline. With a small footprint and the ability to
insert and remove the instrument, there is potential for a
single design of the downstream instrument to be utilized on a
variety of different beamlines. However, the time required for
translating the entire microscope to and from the sample
increases the total time for collecting SHG images and XRD
of the protein. Indeed, the microscope positioning required
substantially more time ( 2 min) than the sample imaging
( 40 s). Furthermore, the absolute accuracy of the translation
stage (in this case,  2 mm) can ultimately dictate the precision
in crystal positioning. In addition, the downstream instrument
did not have transmission-SHG detection capabilities. For
protein crystals, detection in transmission provides substantial
improvements in detection limits for weakly SHG-active
proteins, as thickness greater than the crystals’ coherence
lengths can decrease the overall SHG intensity in the epi
direction (Boyd, 2009; Kestur et al., 2012). The absence of
transmission detection could potentially be remedied by
introducing additional optics or integrating into existing
optical paths.
The direct integration of the upstream system eliminated
the need for a translation stage for inserting the microscope,
as was used with the downstream system. This signiﬁcantly
reduced the time between imaging and XRD, which allowed
for a marked improvement on throughput of data collection.
The upstream system did still require the transmission detection optics to translate in and out for XRD collection in
transmission, but epi-detected SHG can be performed
concurrently with X-ray diffraction, with only a factor of three
reduction in signal intensity with the mini-beam collimator
in place. The positioning of the collection optics does not,
however, require precise realignment allowing for a signiﬁcant
improvement on the translation time, as compared with the
downstream instrument, where the entire microscope requires
translation with high precision. The upstream system had
some design trade-offs to accommodate the existing optical
path, which in part accounted for the lower infrared (IR)
throughput and available power in the upstream system. The
biggest losses came from the incident objective in which 80%
of the IR power was lost from reﬂections because it was not
designed for IR incident light. Choosing optics with a more
broadband anti-reﬂective coating (ARC) will signiﬁcantly
improve the power throughput. Testing performed in-house,
with an IR-ARC objective, resulted in a doubling of the
IR transmittance, corresponding to an anticipated four-fold
improvement in signal at the sample (unpublished). The
multiple imaging modes (SHG and TPE-UVF), as well as both
epi and transmission detection, improves the ability of the
upstream system to detect protein crystals that could otherwise be missed on the downstream system.
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Based on these combined results, integrating a NLO
microscope with a synchrotron XRD instrument complements
stand-alone X-ray raster scanning for crystal centering in three
key respects. First, it is expected to minimize radiationinduced sample damage compared with X-ray raster techniques for X-ray labile crystals or small crystals difﬁcult to
quickly detect at low X-ray ﬂux (Kissick et al., 2013). Second,
NLO microscopy signiﬁcantly increases the spatial resolution
and reduces the total acquisition time for the determination of
crystal location. For a large sample area (150  150 mm)
scanned with a small beam size (5  5 mm), X-ray raster
images for the protein crystals typically required approximately 30 min to acquire with a 1 s X-ray exposure time. For
NLO measurements on identical samples, the acquisition time
for the collection of each image was typically <10 s. The
downstream NLO system allows 512  512 pixel images with
40 s acquisitions, and the upstream system allows 150  150
pixel images with 1 s acquisitions, which is roughly a > 104-fold
reduction in the per-pixel acquisition time compared with the
X-ray raster acquisition time per cell ( 3 s per pixel, corresponding to a 1 s exposure, with 2 s of dead-time between
pixel acquisitions). The theoretical resolution of the objective
was 1.6 mm with 2 mm measured spatial resolution. The
downstream NLO system required a total time of 2.5 min for
translation of the microscope from its resting position to the
sample and then back to the resting position following NLO
measurements, resulting in a total acquisition time for each
sample of the order of 3 min, which is still signiﬁcantly faster
and of higher resolution compared with X-ray raster scan
measurements performed on the same sample. In the
upstream system, no dead-time was required for epi-detection
(in fact, SHG imaging can be performed while acquiring
diffraction measurements), and only a few seconds of translation time were required to raise and lower the collection
optics in transmission. Third, for weakly diffracting systems
where rapid automated diffraction scoring is challenging,
NLO measurements may signiﬁcantly increase the ability to
locate protein crystals.

5. Conclusion
Two different designs of integrated NLO instruments were
constructed and characterized targeting applications for
automated sample positioning. The systems were evaluated
using protein crystals (TsUCH37-UbVME, kOR-T4L, cPAH,
Intimin) and ﬁbers ( -cellulose). Both NLO and XRD
exhibited good agreement for crystal positioning, consistent
with previous off-line measurements speciﬁcally targeting
protein crystals (Kissick et al., 2013). The integrated NLO and
synchrotron XRD instrument was found to enable precise
centering of -cellulose samples for ﬁber diffraction without
requiring the development of an application-speciﬁc analysis
algorithm. The NLO instrument produced images with < 10 s
image acquisition times, compared with 3–60 min for X-ray
rastering performed at much lower spatial resolution. By
nature of the higher resolution of NLO image acquisition, the
per-pixel raw data acquisition time was approximately ﬁve
J. Synchrotron Rad. (2013). 20, 531–540

orders of magnitude faster than X-ray raster scanning. Once
fully developed, NLO imaging may serve to identify regions of
interest for targeted X-ray scanning, or ultimately serve as the
sole or primary method for precise automated crystal positioning, such that all of the X-rays striking the crystal are
dedicated to structure elucidation.
Despite these successes, a relatively small variety of crystals
were used to characterize the instruments in this initial study.
Further studies on a greater diversity of protein crystals will
help deﬁne the scope of use for NLO methods in automated
centering. Additionally, the present study focused exclusively
on the hardware for visualization, and not on subsequent
algorithms for image analysis and automated crystal positioning. Higher contrast afforded by NLO imaging has the
potential to signiﬁcantly improve the reliability of such algorithms if the combined techniques of SHG and TPE-UVF
provide sufﬁcient protein crystal coverage for general-purpose
use.
These studies provided a foundation for future efforts
combining NLO measurements with synchrotron X-ray
diffraction. The data presented here support the use of the
NLO microscopy for automated or manual crystal centering
prior to or in lieu of raster scanning. Potential scope of use
where all optical crystal positioning would be preferred
includes the analysis of smaller crystals (< 5 mm), where the
low crystal volume may present challenges for rapid crystal
positioning by X-ray raster scanning. SHG also enables positioning of ﬁbrous material exhibiting ﬁber diffraction, such as
cellulose, collagen, chitin etc. Further potential applications
include defect studies, X-ray damage studies and studies of
active pharmaceutical ingredients.
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